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ABSTRACT OF THE DISSERTATION
Development and study of inhibitors of heat shock protein 70 induction
By
Rongsheng Wang
Doctor of Philosophy in Chemistry
Washington University in St. Louis, 2010
Professor John-Stephen A. Taylor, Chairperson

Tumor and cancer cells that over express heat shock protein 70 (HSP70) are found to be
multidrug resistant and thermo tolerant, creating a hurdle to existing therapy. Although
HSP70 is recognized as an increasingly important drug target, the protein structure of this
highly conserved chaperone remains challenging for direct targeting. An alternative
strategy is to inhibit the transcription of HSP70. Among known small molecule
inhibitors of HSP70 induction, quercetin has very low toxicity and has the advantage of
being easily modified for structure-activity studies. One part of the dissertation focuses
on the identification of quercetin derivatives with improved specificity and activity, and
to determine the protein targets of quercetin responsible for inhibition of heat shock
induction of HSP70. A library of quercetin derivatives was synthesized and screened for
their ability to inhibit HSP70 induction and at the same time not enhance HSP27
phosphorylation. The derivatives that inhibit HSP70 induction were also found to be
inhibitors of both Ck2 kinase and CaMKII kinase that are known to activate heat shock
transcription factor 1 that leads to HSP70 induction. A biotinylated quercetin affinity
ii

agent was also developed that was able to pull down the CK2 kinase target in vitro and
several other proteins in vivo under UVA irradiation. In collaboration with mass
spectrometry center, these unknown protein targets were identified by proteomic studies,
and found to be previously identified chemotherapeutic targets.
Another goal of this dissertation was to develop polyamide-based gene inhibitors of heat
shock induction that interfere with the binding of the heat shock transcription factor. A
series of polyamides that targeted the heat shock elements were designed and synthesized
and demonstrated to bind the target DNA by DNase I footprinting. These polyamides
were evaluated by gel shift assay for their ability to block binding of the heat shock factor
and the most effective polyamide was shown to decrease HSP70 expression in Jurkat
cells by western blot assay.
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Chapter 1. Introduction

1

Background of heat shock proteins
Heat shock proteins (HSPs) are so-called stress proteins that are found in nearly all living
organisms and are believed to be part of a stimuli induced mechanism that protects cells
from various environmental and physiological challenges ranging from exogenous toxins
to heat, oxidative stress, and ischemia/reperfusion injuries [1-5] (Figure 1.1). Most heat
shock proteins function as conserved molecular chaperones to work together with cochaperones in folding newly synthesized proteins/peptides, refolding denatured or
damaged proteins/peptides, and at the same time helping the assembly of protein
complexes as well as the intra/extra cellular transportation of certain proteins [6]. Heat
shock proteins have been categorized according to their molecular weight class, among
which heat shock protein 70s (HSP70s) and heat shock protein 90s (HSP90s) are the
most highly conserved and prevalent, existing in almost all organisms from E. coli to
humans [3, 7].

Heat shock proteins and cancer
Consistent with their diverse activities, heat shock proteins have been found to participate
in oncogenesis, promote tumor survival, and induce resistance to chemotherapeutic
agents [8-11]. Cancer cells are believed to be under stress due to unnatural growth
properties which makes them produce high amounts of proteins. The housekeeping
functions and stimuli resistance of heat shock proteins are thus needed by cancer cells to
maintain high-speed reproduction and metabolism, and to inhibit apoptosis by various

2

therapeutic agents. Over-expression of HSP90s and HSP70s in many tumors [12]
correlates with the proliferation and survival of oral [13], gastrointestinal [14], colorectal
[15], histiocytic lymphoma [16], and breast cancers [17, 18]. Thus heat shock proteins
have recently become of interest as targets for cancer therapy [19].

Importance of HSP70 inhibition
Our interest in HSP70 initially came from the observation that its overexpression
increased cellular resistance to hyperthermia and thus radiosensitization. HSP70 knockout mice not only showed increased sensitivity to necrosis and inflammation, but also
displayed genomic instability and enhanced radiosensitivity [7]. HSP70 inhibitors would
thus be promising drug candidates to be administrated in cancer therapy to improve the
effect of clinical radiosensitization. Additionally, HSP70 can inhibit cell apoptosis by
both caspase-dependent and independent mechanisms [20], stabilize lysosomes [21], and
significantly down-regulate NF-B activity [22] and inflammatory responses; all of
which are necessary for cancer cell survival [23]. Likewise, depletion of endogenous
HSP70 levels in transformed cells induces cell death [24, 25]. Therefore drugs that can
inhibit HSP70 could be not only useful as adjuvants in cancer chemotherapy but also as
anti-cancer agents themselves.

HSP70 protein types, structure and induction mechanism

3

Members of the human heat shock protein 70 family have been found to exist in all the
cellular locations with different isoforms (Table 1.1) [26], five of which are constitutively
expressed in cytosol and nucleus (HSP70A2, HSP70A1L, HSPA8), endoplasmic
reticulum (HSPA5) and mitochondria(HSPA9). While most HSP70 proteins are present
at low basal levels in normal cells and over-expressed in cancer cell lines, some HSP70s
are substantially upregulated by stress stimuli, through mediation by heat shock
transcription factor 1. Stress induced HSP70 transcription is a complicated process,
which involves heat or stress-induced release of heat shock transcription factor 1 (HSF-1)
from a complex with HSP90, followed by translocation to the nucleus where it is
phosphorylated by Cam KII and CKII kinases, trimerization, and then binding to the heat
shock elements (HSE) of the HSP70 gene [27]. Three types of inducible HSP70 have
been found so far, among which HSPA1A and HSPA1B are the most homologous and
recognize the same heat shock elements, while HSPA6 is less homologous and
recognizes different heat shock elements (Table 1.2).
Both the heat shock protein 90 and heat shock protein 70 families possess N-terminal
nucleotide binding domains (NBD) that bind to ATP and make use of ATP hydrolysis to
carry out their functions [28]. The HSP70 family also has a C-terminal substrate-binding
domain (SBD) for binding linear peptides and exposed regions of folded proteins. The
two domains of HSP70 are connected by a short linker [29] (Figure 1.2). It is worth
noticing that the NBD part of HSP70 (MW around 40 kDa) further consists of two subdomains, I and II, each being divided to two regions (a, b) respectively. ATP interacts
with subdomains Ia and IIa in a nucleotide binding motif related to those of hexokinase,
actin and glycerol kinase, which leads to the binding of HSP70 to ATP in high affinity
4

with a nanomolar Kd [28, 29]. The NBD domain of HSP90 is significantly different in
structure, belonging to the GHKL type, and binds ATP with a weaker micromolar Kd
[28].

Development of HSP70 inhibitors
The ATPase site of HSP90 is a target for the well-known small molecule inhibitors 17allylamino-17-demethoxy-geldanamycin (17AAG) and 17-(dimethylaminoethylamino)17-demethoxygeldanamycin (17DMAG)[30-32] which have been successfully advanced
into clinical trials (Figure 1.3). Despite the identification of HSP70 as a potential drug
target due to its importance role in cancer and apoptosis [33], neurodegenerative and
infectious diseases [29]; only a few inhibitors have been developed so far to directly
interact with either the ATP binding domain, such as VER-155008, or the substrate
binding domain of HSP70, such as phenylethynesulfonamide (Figure 1.3) [28, 34, 35].
The more hydrophilic nature of the HSP70 drug targeting sites and a high affinity ATP
binding site have limited the development of HSP 70 inhibitors [28]. An alternate
approach is to inhibit HSP70 expression through inhibitors of heat shock transcription
factors.
To date, several methods have been reported to deactivate transcription factors by
inhibiting either its activation (phosphorylation and oligomerization) [36], or blocking its
contact with the DNA promoter by artificial oligomer mimics or polyamides [37-39]
(Figure 1.4). In the latter case, peptide nucleic acid (PNA) have been developed to bind
to the major groove of DNA, while polyamide composed of N-methyl pyrrole and N5

methyl imidazole building blocks that are linked together by amide bond, targets at the
minor groove [37-39]. Both ways would limit the extent of binding of transcription
factors to the major groove.
There are also some natural products that appear to interfere with heat shock transcription
factor function (Figure 1.5). The most potent of these inhibitors is the diterpenoid
triepoxide, triptolide, which induces pancreatic cancer cell death in vitro and in vivo via
inhibition of HSP70 expression [40] by interfering with the heat shock factor
transactivation process [41]. Unfortunately, triptolide has severe toxic side effects in
animals and humans, and its structural complexity does not make it an attractive target for
further synthetic development. Quercetin is another small molecule which belongs to the
flavonoid family with multiple medicinal properties [42]. Initially extracted from red
wine, quercetin was subsequently found to exist widely in leaves, fruits, and vegetables
[43], and is available as a dietary supplement. Quercetin inhibits HSP70 induction at a
concentration of 100 µM and inhibits the phosphorylation of heat shock transcription
factor though the detailed mechanism of action and other interacting targets remain
unknown. Although the bioactivities of flavonoids are notoriously non-specific,
elucidation of the mechanism of action of quercetin in inhibiting HSP70 induction as well
as its other targets would be very useful and fundamentally important in future drug
design. Given the chemical structure of quercetin that would appear to be relatively easy
to modify and its low toxicity [42], quercetin derivatives with improved efficacy and
specificity for HSP70 inhibition could have potential to be chemotherapeutic drugs.
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Goals of this dissertation
The goal of this dissertation is to develop inhibitors of HSP70 induction that have
potential as chemotherapeutic agents and to probe the biological mechanisms behind their
inhibition (Figure 1.6). Since directly inhibiting heat shock protein 70 has been
problematic [28], a more feasible way would be to interfere with heat shock transcription
factors. In chapter 2, I describe the structure and activity studies of quercetin derivatives
that are known to inhibit heat shock protein 70 induction via interfering with heat shock
transcription factor activation. This was carried out by mapping the non-active sites of
quercetin and identifying derivatives with improved specificity and activity. I also
investigated the effect of these derivatives on the putative kinases thought to be involved
in the activation of heat shock transcription factor, and hence HSP70 induction. In
chapter 3, I conjugated a biotin molecule to a non-active site of quercetin and used it to
pull down possible target proteins of quercetin in vivo. In chapter 4, I describe the
development of much larger, polyamide-based gene targeting agents that interfere with
the binding of heat shock transcription factors to HSP A1A/HSP A1B promoters to
inhibit the induction of heat shock protein 70 in vivo.
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Table 1-1. HSP70 family and properties.
Name

Altern

Homology

HSP
Locus

Localization

Stress
Inducible

Hsp70-1a

70,72,70-1

100

A1A

Cyt, Nucl

Yes

Hsp70-1b

70, 72, 70-1

99

A1B

Cyt, Nucl

Yes

Hsp70-1t

70-hom

91

A1L

Cyt, Nucl

No

Hsp70-2

70-3,A2

84

A2

Cyt, Nucl

No

Hsp70-5

Bib, Grp78

64

A5

ER

No

Hsp70-6

70B’

85

A6

Cyto, Nucl

Yes

Hsc70

70‐8,73

86

A8

Cyto, Nucl

No

mt Hsp 70

Mort,Grp75

A9

Mito

No

Table 1-2. Heat shock elements of stress-inducible human HSPA1A, A1B and A6.
(Bases of HSPA1B and HSPA6 that are different from HSPA1A are in bold size)

Site 1

Site 2

Site 3

Site 4

HspA1A

G CGAAA ACCCT

GGAAT

ATTCC C

HSPA1B

G CGAAA CCCCT

GGAAT

ATTCC C

HSPA6

G GGAAG GTGCG

GGAAG

GTGCG C
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Figure 1.1 General role of heat shock proteins 70 (Hsp70) and 90 (Hsp90) as
protein chaperones in the stress response.
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Figure 1.2 Structure of E. coli heat shock protein 70 (HSP70) (PDB code: 2KHO)[29]
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Figure 1.3 (A) Known inhibitors that target HSP90 (B) Known inhibitors that target HSP70 [28].
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Figure 1.4 General sequences of events leading to activation of protein expression showing the various steps
which inhibitors can target. Step 1. Phosphorylation; Step 2. Oligomerization; Step 3. Binding to promoter; Step
4. Initiation of transcription. (The order of step 1, step2, and step 3 are variable depending on the transcription
factor and cell line)
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Figure 1.5 Natural product inhibitors of HSP70 expression.
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Chapter 2, 3

Chapter 4

Figure 1.6 Subject areas of this dissertation
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Chapter 2.
Inhibition of Heat Shock Induction of Heat Shock Protein
70 and Enhancement of Heat Shock Protein 27
Phosphorylation by Quercetin Derivatives

The text of this chapter was taken in part from a manuscript coauthored with
Kao Jeffrey L-F, Hilliard Carolyn A, Pandita Raj K, Roti Roti Joseph L, Hunt Clayton R,
Taylor John-Stephen (Washington University in St Louis).
(Journal of Medicinal Chemistry, 2009; 52(7); 1912-1921.)
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Abstract
Inhibitors of heat-induced heat shock protein 70 (HSP70) expression have the potential to
enhance the therapeutic effectiveness of heat-induced radiosensitization of tumors as well
as other anti-cancer treatments. Among known small molecule inhibitors, quercetin has
the advantage of being easily modified for structure-activity studies. Herein, We report
the ability of five monomethyl and five carbomethoxymethyl derivatives of quercetin to
inhibit heat-induced HSP70 expression and enhance HSP27 phosphorylation in human
cells. While quercetin and several derivatives inhibit HSP70 induction and enhance
HSP27 phosphorylation at Ser78, other analogues selectively inhibit HSP70 induction
without enhancing HSP27 phosphorylation that would otherwise aid in cell survival. We
also show that good inhibitors of HSP70 induction are also good inhibitors of both CK2
and CamKII, kinases that are known to activate HSP70 expression by phosphorylation of
heat shock transcription factor 1. Derivatives that show poor inhibition of either or both
kinases are not good inhibitors of HSP70 induction, suggesting that quercetin’s
effectiveness is due to its ability to inhibit both kinases.
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Introduction
Recently it has been shown that inhibition of HSP70 in tumor cells by either a gene
knockout [1] or by antisense agents [2] enhances heat-induced radiosensitization (HIR)
and tumor apoptosis. It would be therefore highly desirable to have a small molecular
inhibitor of heat induced HSP70 that could be administered either prior to HIR to further
enhance killing or directly as part of anti-cancer chemotherapy.
Heat induction and regulation of HSP70 is a rather complicated process, involving
initial release of the heat shock transcription factor 1 (HSF1) from HSP90, followed by
trimerization, translocation into the nucleus, and then binding to the heat shock element
(HSE) (Figure 2.1) [3-5]. For transcription to occur the trimer must first be activated by
phosphorylation at serine 230 with calcium/calmodulin kinase II (CamKII) [6] and/or
threonine 142 by casein kinase 2 (CK2) [7]. In contrast, phosphorylation at other sites
down regulates the transcriptional activity of HSF1. For example, phosphorylation at
serine 121 by mitogen activated kinase 2 (MK2) causes unfolding of HSF1 and rebinding
to HSP90 [8]. Likewise, phosphorylation of serine 307 by ERK or serine 363 by JNK
inactivates HSF1 [9].
A number of small molecule inhibitors of heat-induced HSP70 expression have
been reported, the most effective of which are triptolide and quercetin (Figure 2.2) [10].
Triptolide is a highly functionalized molecule that has been found to prevent heat shock
HSF1 from activating transcription in the steps following trimerization, phosphorylation
and DNA binding [11]. Quercetin, on the other hand, is a structurally much simpler
natural product of the flavone family, that has been reported to have a wide variety of
biological activities [12, 13], one of which is the inhibition of heat-induced HSP70
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expression by as yet unknown mechanisms [14, 15]. Quercetin inhibits a number of
kinases [16], including CK2 which has been shown to enhance HSP70 induction through
phosphorylation of HSF1 threonine 142 [7]. It is therefore possible that quercetin inhibits
HSP70 induction by blocking phosphorylation of HSF1 by CK2 and/or CamKII [6].
Quercetin is also metabolized in vivo and it is possible that some of the metabolites are
the active pharmaceutical agents [17].
To guide the design and synthesis of biotinylated probes for identifying the
target(s) of quercetin inhibition of heat-induced HSP70 expression, and to enhance its
specificity, we synthesized all of the mono-methyl (Figure 2.3, 2.4) and selected
carbomethoxymethyl (Figure 2.5, 2.6, 2.7) derivatives of quercetin. Systematic
methylation ("methyl scanning") has been previously proposed and validated as a general
method for mapping the interactions of biologically active molecules with receptors and
for designing affinity probes [18, 19]. The quercetin derivatives were tested for their
ability to inhibit heat-induced HSP70 expression and modulate HSP27 phosphorylation in
human Jurkat cells and human HeLa cells, respectively, by Western blot analysis. Two
classes of active agents were discovered, one that both inhibits HSP70 induction and
enhances HSP27 phosphorylation, and another that inhibits HSP70 induction without
enhancing HSP27 phosphorylation. Quercetin and derivatives that inhibited HSP70
induction were also found to inhibit both CK2 and CamKII kinases. On the other hand,
derivatives that showed poor inhibition of either or both kinases did not inhibit HSP70
induction, indicating that quercetin's effectiveness is due to its ability to inhibit more than
one enzyme.
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Results
Chemistry
Synthesis of O-alkylated quercetin derivatives. To determine the importance of
individual hydroxyl groups on the inhibition of heat-induced HSP70 expression and other
biological activities, I synthesized the mono-methylated quercetin derivatives D2, D3,
D4, D6, and D7 according to previously reported procedures [20]. Because we ultimately
intend to attach affinity tags such as biotin to quercetin to help in identifying the protein
target(s) of quercetin activity, I also synthesized a number of carboxymethylated
derivatives by the same synthetic route (Figure 2.5, 2.6, 2.7). Thus, quercetin was
benzylated to give 20% of the tribenzyl derivative 2 and 60% of the tetrabenzyl
derivative 1. The tribenzyl derivative was selectively carbomethoxymethylated at the 3'OH to give 4, whereas the tetrabenzyl derivative was carbomethoxymethylated at the 5OH to give 3. The products were debenzylated with palladium hydroxide and hydrogen
to afford the methyl esters D8 and D1 respectively.
To carbomethoxymethylate positions 3 and 7, I utilized the 3', 4'-diphenylmethylene
derivative of quercetin, compound 5 (Figure 2.6). This derivative reacted with
methylbromoacetate under basic conditions at the 3-OH to give 6, which then afforded
the carboxymethyl derivative D5 following removal of the diphenylmethylene group by
refluxing with acetic acid, which also hydrolyzed the ester. To obtain the O7 derivative,
the 3-OH of compound 5 was first benzylated to give 7 which was then
carbomethoxymethylated at the 7 position. Removal of the benzyl and
diphenylmethylene groups was carried out in two steps by hydrogenolysis with palladium
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hydroxide followed by hydrolysis with acetic acid and water which also unexpectedly
hydrolyzed the ester to the carboxymethyl product D9.
Many attempts to methylate D9 to produce D10 were unsuccessful and so other synthetic
routes were investigated. The best of these involved a previously reported method for
selectively methylating or benzylating the 7-OH of quercetin by treatment of quercetin
pentaacetate with the alkylating agent in the presence of potassium carbonate and
potassium iodide in acetone [22]. Thus treatment of quercetin pentaacetate [23] under
these conditions with methyl bromoacetate yielded compound 10 which could be
deacetylated in high yield under neutral conditions with N-methyl-2dimethylaminoacetohydroxamic acid [24] to give D10 (Figure 2.7). This deacetylation
method was chosen as more basic conditions, such as sodium methoxide and methanol at
0 oC, tend to result in air oxidation of the product [25] whereas more acidic conditions
lead to hydrolysis of the methyl ester on the other hand.
Structural characterization. The sites of alkylation in all the compounds were
confirmed by analysis of the coupling patterns in the 1D 1H NMR spectra together with
correlations in the COSY, HMQC and HMBC spectra. As an illustration, the B ring
hydrogens H5' and H6' of D1 (Figure 2.8) and D10 (Figure 2.9) were assigned by the
large ortho coupling, and the strong crosspeak in the COSY spectrum (crosspeak a, panel
A). These assignments led to the assignment of H2' through meta coupling with H6' that
could be detected in the 1D 1H NMR spectrum. The carbons directly attached to these
protons could then be assigned through the HMQC spectra (Panel B). The hydrogen
signal at 10 ppm in D1 could then be assigned to the 4'-OH by the presence of a long
range correlation to C5' at 116 ppm (Figure 2.8, crosspeak e) and to a quaternary carbon
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signal at 146 ppm (crosspeak b) together with the absence of a correlation to C2' in the
HMBC spectrum (panel C). The signal at 146 ppm could therefore be assigned to C3'
which in turn showed a correlation to the  hydrogen of the carbomethoxymethylene
group (crosspeak d, panel C). The position of the carbomethoxymethylene group in D10
could be assigned to O7 via a correlation between the -methylene protons and a
quaternary carbon signal at 162 ppm (Figure 2.9, crosspeak d in panel C). The signal at
162 ppm could be assigned to C7 via multiple bond correlations to the two meta coupled
protons in the A ring in the HMBC spectrum (crosspeaks b & c in panel C).

Biological Studies
Inhibition of heat induced HSP70 expression by quercetin derivatives. I collaborated
with Dr Clayton Hunt to examine the ability of the quercetin and its derivatives to inhibit
heat induced HSP70 expression, we chose human Jurkat cells due to their low basal level
of HSP70 expression and the large induction upon heat shock. Western blot analysis of
the cellular proteins in Jurkat cells following heat shock revealed that pre-heat treatment
with the quercetin derivatives D1, D2, D7 and D10 all had a similar inhibitory effect on
HSP70 induction as did quercetin, indicating that the 3' and 7 hydroxyls are important for
activity (Figures 2.10A, Table 1). Compound D1 which bears a carbomethoxymethyl
group at O3' is not as good an inhibitor as D2, which bears a methyl group, indicating
that the 3' hydroxyl group occupies a more sterically constrained site in the target protein
than does the 7 hydroxyl group. Compound D9, which bears a carboxylic acid group at
O7, does not inhibit HSP70 like D10 which bears an ester group, presumably because it
forms a salt at neutral pH that greatly reduces its membrane permeability.
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Enhancement of HSP27 phosphorylation. In examining the effects of quercetin
treatment on other heat shock proteins, we found that quercetin enhances HSP27
phosphorylation at Ser78 in the absence of heat shock. Phosphorylated HSP27 has antiapoptotic activity [26] which would tend to counteract any lethal effects achieved from
inhibiting HSP70 induction. Thus, it would be highly desirable to inhibit HSP70 without
enhancing phosphorylation of HSP27. The HSP27 studies were carried out in HeLa cells,
which unlike Jurkat cells, have a high basal level of HSP27, making it easier to detect
drug-induced phosphorylation of HSP27 by Western analysis. HeLa cells, however, are
not as suitable for concurrent inhibition studies of HSP70 induction since they have high
basal level of HSP70. Only D7 and D10 showed enhancement of HSP27
phosphorylation in HeLa cells, and both of these compounds also showed good to strong
inhibition of HSP70 induction in Jurkat cells (Figure 2.10 B, Table 1). On the other
hand, D1 and D2 which were also good inhibitors of HSP70 induction did not activate
HSP27 phosphorylation.
Effect of quercetin on HSF1 binding to the HSE. In order to gain insight into the
mechanism by which quercetin inhibits HSP70 induction, gel mobility shift analysis was
carried out to examine binding of heat shock element (HSE) DNA by heat shock
transcription factor 1 (HSF1), the transcription factor responsible for heat induced HSP70
gene transcription (Figure 2.11A upper panel). No HSF1/HSE complex was detected
with nuclear extracts prepared from control, non-heated Jurkat cells but the complex was
readily detected with extracts prepared immediately following a 43 C 30 min heat shock.
The amount of complex increased by 1 h post-heat then declined by 4 h post-heat and
returned to control levels by 8 h post-heat. In Jurkat cells treated 1 h prior to heat shock
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with quercetin, however, only a very low level of complex formed in extracts from heated
cells. Since an identical low level of complex was also detected in extracts from
quercetin-treated but non-heated cells, this response appears to be due to drug induced
cell stress not heat. In contrast to Jurkat cells, HeLa cells displayed an accelerated loss of
HFS1/HSE complex during recovery from heat shock with nearly undetectable levels by
4 h post-heat (Figure 2.11A, lower panel). Moreover, quercetin treatment did not inhibit
HSF1/HSE complex formation in heated HeLa cells as it did in Jurkat cells suggesting a
complex interaction between the drug and possibly multiple cell specific factors.
Further information about the mechanism by which quercetin inhibits heat-induced
HSP70 expression was obtained by Western blot analysis of the nuclear extracts for the
presence and size of the HSF1 protein (Figure 2.11B). In non-heated Jurkat control cells,
HSF1 is not detected in nuclear extracts while only a very low level can be detected in
HeLa cells. Surprisingly, nuclear extracts from quercetin treated Jurkat cells contained
significant levels of HSF1 while similar HeLa cell extract contained the very low levels
detected in untreated extracts. In both Jurkat and Hela cells, heating increased HSF1
nuclear extract levels and induced a corresponding decrease in gel mobility that reflects
the increased level of heat-induced phosphorylation required for transcriptional activity
[6]. While quercetin treatment did not block the heat-induced increase in nuclear HSF1
levels in either Jurkat and HeLa cells, the drug did inhibit the decrease in HSF1 mobility,
presumably by inhibiting the critical phosphorylation modifications required for
transcription activation. Thus in Jurkat cells, quercetin treatment appears to affect at least
two steps in heat induced HSP70 expression, HSF1 post translational modification and
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DNA binding activity. Quercetin treatment of HeLa cells does not result in loss of HSF1
DNA binding activity but does appear to inhibit heat induced phosphorylation.
Kinase inhibition assays. We then determined whether or not the activity of the
quercetin analogs correlated with their ability to inhibit either or both CKII and CamKII
kinases that have previously been shown to phosphorylate HSF1. I used an enzymelinked inhibition assay that utilizes luciferase to quantify the amount of ATP remaining in
a kinase reaction [27]. The IC50 values for quercetin and D1-D10 are listed in Table 2 in
comparison to their relative ability to inhibit HSP70 induction. Good inhibition of
HSP70 induction appears to correlate with good inhibition of both CK2 and CamKII.
Quercetin derivatives that showed poor inhibition (IC50 > 100 M) of either or both
kinases showed little to no ability to inhibit heat induction of HSP70. The only exception
was D9 which was a very good inhibitor of both kinases, but showed no ability to inhibit
HSP70 induction, which we attribute to the presence of a carboxylate which reduces
membrane permeability.

Discussion
Inhibition of heat-induced HSP70 expression has been shown to enhance
radiosensitization by heat [1, 2] and thus small molecule inhibitors of HSP70 induction
have potential therapeutic value. Quercetin has long been known to inhibit heat-induced
HSP70 expression, though the exact mechanism is unclear. The results herein suggest
that quercetin treatment blocks heat-induced phosphorylation of the HSF1 transcription
factor that is responsible for inducing HSP70 expression. In Jurkat, but not HeLa cells an
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additional level of inhibition appears to be loss of HSF1 HSE element binding capacity,
which has also been reported in quercetin/heated human COLO 320DM cells [28].
Unfortunately, quercetin is also well known to affect many additional biological
processes, probably as a result of its ability to inhibit a number of different kinases [16],
which diminishes its potential as a therapeutic. On the other hand it seems reasonable
that the specificity for inhibiting HSP70 induction could be increased by selective
modification of quercetin. Also identifying the target of quercetin responsible for
inhibiting HSP70 induction could aid in the development of more selective inhibitors. To
these ends we have been able to show that the C7 and C3' hydroxyls on quercetin can be
derivatized with a bulky carbomethoxymethyl group without affecting its ability to inhibit
heat induced HSP70, and could therefore be used to attach a biotin affinity probe.
The finding that the 3' and 7 hydroxyls of quercetin can be modified without
affecting inhibition of heat-induced HSP70 expression suggested modification of these
hydroxyls might also increase the selectivity by interfering with binding to other protein
targets. Quercetin has been crystallized with a number of kinases, and inspection of the
crystal structures reveals that the 7-OH of quercetin is buried in the Hck kinase complex
[29] as well as in the F1-ATPase [30] and therefore O7 derivatives would not be expected
to inhibit these enzymes. The O7 position of quercetin is not buried, however, in the
phosphoinositide 3-kinase complex [31], but the O3'-position is, suggesting that quercetin
derivatized at both the O7 and O3' positions would also not inhibit any of these enzymes,
but would still inhibit HSP70 induction. This class of doubly derivatized quercetin
remains to be synthesized and examined for its ability to inhibit HSP70 induction.
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Given that quercetin is a well known kinase inhibitor, and that the pathway for
heat induction of HSP70 expression involves phosphorylation of the heat shock factor 1
(HSF1) by CK2 and CamKII kinases, we investigated whether the two might be
correlated. It has previously been established that quercetin is an inhibitor of CK2
kinase, but its ability to inhibit CamKII kinase has not been reported. we now show that
quercetin is also a good inhibitor of CamKII and that quercetin derivatives D1, D2, D7
and D10, that are good inhibitors of HSP70 induction, are also good inhibitors of both
CK2 and CamKII kinases. Quercetin derivatives that were good inhibitors of only one or
neither of the two kinases, however, were not good inhibitors of HSP70 induction. It
would seem that full activation of HSP70 by HSF1 may only require phosphorylation by
either CK2 or CamKII, both of which quercetin and derivatives D1, D2, D7 and D10 are
able to inhibit due to their broader specificity.
The ability of quercetin to enhance phosphorylation of HSP27 has not been
previously recognized. Phosphorylation of serine 78 has been shown to be carried out by
MAPKAP2 kinase [32], which in turn is activated by MAPK kinase. It is not clear how
quercetin activates phosphorylation of HSP27, as inhibiting any of the kinases in the
pathway should abolish activation. Activation of HSP27 has been associated with poor
prognosis and resistance to chemotherapy or radiation [33] and so the quercetin analogs
D1 and D2 which retain the ability to inhibit HSP70 induction without inducing HSP27
phosphorylation may have superior therapeutic properties to D7 and D10.
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Conclusion
One goal of this study was to find derivatives of quercetin that could be elaborated into
affinity probes to identify the targets responsible for inhibition of heat-induction of
HSP70. We identified two such derivatives, which are now in the process of being
converted to biotinylated probes. In the course of evaluating these derivatives, we
discovered that their ability to inhibit HSP70 induction correlated with their ability to
inhibit both CK2 and CamKII, kinases that are known to activate HSP70 transcription by
phosphorylating HSF1. Derivatives that show poor inhibition of either or both kinases
are poor inhibitors of HSP70 induction, suggesting that HSP70 expression can be
activated by either kinase. This would appear to be a case in which making the drug
more specific reduces its effectiveness, suggesting that future screens for HSP70
inhibitors be carried out for activity against both kinases. In collaboration with Dr
Clayton Hunt, I have also discovered that quercetin enhances the phosphorylation of
HSP27 required for its anti-apoptotic action, which would serve to diminish the
radiosensitizing or antitumor effects of inhibiting HSP70 induction. Two derivatives of
quercetin, D1 and D2, were found, however, that could inhibit HSP70 induction without
enhancing HSP27 phosphorylation, but the degree to which they may be able to enhance
heat-induced radiosensitization remains to be determined. In addition to probing the
mechanism of inhibition of HSP70 induction, this family of methylated quercetin
derivatives might also be useful for mapping out interactions with other targets.
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Experimental section

Abbreviations
17AAG, 17-allylamino-17-demethoxy-geldanamycin; 17DMAG, 17(dimethylaminoethylamino)-17-demethoxygeldanamycin; CaMKII, Ca2+/calmodulindependent protein kinase II; CK2, casein inase II; COSY, correlation spectroscopy;
DCM, dichloromethane; DMEM, dulbecco’s modified essential medium; DMF, dimethyl
formamide; DMSO, dimethyl sulfoxide; DTT, dithiothreitol; EDTA,
ethylenediaminetetraacetic acid; ERK, extracellular signal-regulated protein kinase; ESI,
electrospray ionization; EtOAc, ethyl acetate; EtOH, ethanol; FAB, fast-atom
bombardment; HIR, heat-induced radiosensitization; HMBC, heteronuclear multiple bond
coherence spectroscopy; HMQC, heteronuclear multiple quantum coherence
spectroscopy; HSE, heat shock element; HSF1, heat shock factor 1; HSP, heat shock
protein; IC50, 50% inhibitory concentration; JNK, c-Jun N-terminal kinase; MeOH,
methanol; MK2(MAPKAP2), mitogen-activated protein kinase activated protein kinase
2; RPMI, roswell park memorial institute; Ser 78, serine 78; THF, tetrahydrofuran; TLC,
thin layer chromatography; Tris, tris(hydroxymethyl)aminomethane;

General procedures
Reagents and solvents were obtained from either Sigma Aldrich or Alfa Aesar.
Anhydrous solvents were distilled and then stored over activated 5 Å molecular sieves.
All other commercial materials were used without further purification unless otherwise
stated. Analytical thin-layer chromatography was performed on Aldrich Silica gel 60 F254
plates (0.25 mm) and compounds were visualized with UVG-54 mineral light UV lamp at
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254 nm. Flash column chromatography was conducted using the indicated solvent on E.
Merck silica gel 60 (40-63 m). 1H NMR and 13C NMR spectra were recorded with
Mercury-300, Inova-500 and Inova-600 (Varian Assoc., Palo Alto, CA) spectrometers
and the data were processed with VNMR software. Proton and carbon chemical shifts
were measured in parts per million (ppm) downfield from an internal TMS standard.
Proton spectra were obtained in [D6] DMSO with a 8200-Hz spectral width collected into
32K data points. Carbon spectra were obtained with a 34000-Hz spectral width collected
into 64k data points. The gradient COSY experiments were collected with a spectral
width of 8200 Hz and 2048 complex points in F2 dimension and 512 real points in F1
dimension. The proton-detected heteronuclear multiple quantum coherence (HMQC)
spectra were recorded using a 0.3 s 1H-13C nulling period. The 90o 1H pulse width was
9.8 s and the 90o 13C pulse width was 12.5 s. Phase sensitive 2D spectra were
obtained by employing the Hypercomplex method. A 2 x 256 x 2048 data matrix with 16
scans per t1 value was collected. Gaussian line broadening was used in weighting both
the t2 and the t1 dimension. After two-dimensional Fourier transform, the spectra resulted
in 512 x 2048 data points, which were phase and baseline, corrected in both dimensions.
Analytical HPLC purity test was performed in System Gold High Pressure Liquid
Chromatography with a solvent pump module 125 and model 168 diode array UV
detector. A Waters XTerra MS C18 (5 µm, 6×250 mm) reverse phase column was used.
Generally a linear gradient of solvent B (80% acetonitrile/water/0.1% trifluoroacetic acid)
in solvent A (water/0.1% trifluoroacetic acid) was from 10% to 30% at the first 20
minutes, then from 30% to 50% in the following 10 minutes, and all the way up to 100%
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in the next 10 minutes. In the final 15 minutes, percentage of solvent B dropped back
from 100% to 10%.
The organic synthesis of mono-methyl quercetin derivatives were based on literature
report [20] (Figure 2.3, 2.4). Compounds D6, D1, D3, D7 were additionally recrystallized twice before further studies on bioactivities. Compound D4 was separated
and purified by HPLC to afford a purity above 95%, before further biological studies.
Compound D6. 1H NMR ([D6]DMSO, 300 MHz) [Figure 2.12] δ 10.73 (s, 1H), 9.49 (s,
1H), 9.28 (s, 1H), 8.67 (s, 1H), 7.65 (d, J=2Hz, 1H), 7.50 (d, J=8Hz, 1H), 6.89 (d, J=8Hz,
1H), 6.48 (d, J=2Hz, 1H), 6.38 (d, J=2Hz, 1H), 3.85 (s, 3H)
Compound D2. 1H NMR ([D6]DMSO, 300 MHz) [Figure 2.13] δ 10.78 (s, 1H), 9.76 (s,
1H), 9.45 (s, 1H), 7.73(d, J=2Hz, 1H), 7.67 (dd, J=8Hz, 2Hz, 1H), 6.92 (d, J=8Hz, 1H),
6.46 (d, J=2Hz, 1H), 6.18 (d, J=2Hz, 1H), 3.85(s, 3H)
Compound D3. 1H NMR ([D6]DMSO, 300 MHz) [Figure 2.14] δ 12.46 (s, 1H), 10.82
(s, 1H), 9.49 (s, 1H), 9.36 (s, 1H), 7.67 (s, 1H), 7.64 (d, J=2Hz, 1H), 7.09 (s, J=8Hz, 1H),
6.43 (d, J=2Hz, 1H), 6.19 (d, J=2Hz, 1H), 3.85(s, 3H)
Compound D7. 1H NMR ([D6]DMSO, 300 MHz) [Figure 2.15] δ 9.65 (s, 1H), 9.51 (s,
1H), 9.31 (s, 1H), 7.73 (d, J=2Hz, 1H), 7.58 (d, J=8Hz, 1H), 6.90 (d, J=8Hz, 1H), 6.71 (d,
J=2Hz, 1H), 6.36 (d, J=2Hz, 1H), 3.86 (s, 3H)
Compound D4. 1H NMR ([D4]CD3OD, 300 MHz) δ 7.63 (d, J=2Hz, 1H), 7.55 (d,
J=8Hz, 2Hz, 1H), 6.90 (d, J=8Hz, 1H), 6.41 (d, J=2Hz, 1H), 6.21 (d, J=2Hz, 1H), 3.79 (s,
3H).
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The selective synthesis of mono-carbomethoxymethyl derivatives was conducted by
similar routes with modifications (Figure 2.5, 2.6, 2.7), as illustrated below.

Compound 4. A solution of 2 (0.60 g, 1.1 mmol) in DMF (20 mL) was mixed
with potassium carbonate (0.19 g, 1.4 mmol) under nitrogen. Methyl bromoacetate
(0.160 g, 1.05 mmol) was then slowly added. The resulting solution was stirred at room
temperature for 12 h, diluted with 40 mL of water and extracted with 60 mL ethyl acetate.
The organic phase was washed with water, dried over anhydrous sodium sulfate and
concentrated under reduced pressure. The residue was purified by flash column
chromatography using DCM/Hexane (85:15) to afford 4 in 90% yield (0.58 g). 1H NMR
(CDCl3, 300 MHz) [Figure 2.16] δ 12.67 (s, 1H, OH), 7.61 (d, J=2Hz, 1H), 7.60 (dd, J=9,
2Hz, 1H), 7.47-7.23 (m, 15H), 6.94 (d, J=9Hz, 1H), 6.45 (d, J=2Hz, 1H), 6.40 (d, J=2Hz,
1H), 5.20 (s, 2H), 5.08 (s, 2H), 5.05 (s, 2H), 4.55 (s, 2H), 3.72 (s, 3H). 13C NMR (CDCl3,
75 MHz) [Figure 2.17] δ 179.0 (C=O), 169.4 (COO), 164.8, 162.3, 156.9, 156.2, 151.3,
147.6, 137.8, 136.8, 136.6, 136.1, 129.0, 128.9, 128.6, 128.5, 128.4, 127.8, 127.6, 124.0,
123.6, 115.9, 114.0, 106.4, 98.9, 93.3, 74.7, 71.1, 70.7, 66.8 (OCH2), 52.4 (OCH3). MS
(FAB) [M+Na+] m/z 667.2, HRMS (FAB) C39H32O9Na [M+Na+], calculated m/z
667.1944, found 667.1932.

35

Compound D1. A suspension of compound 4 (100 mg) was dissolved in a
minimum amount of EtOH/THF (1:1) and treated with 10% palladium hydroxide (0.01
g). The suspension was stirred over night at room temperature under one atmosphere of
hydrogen from a balloon. After filtration with Celite to remove the palladium, the filtrate
was concentrated under reduce pressure, followed by a recrystallization with methanol
and water to give D1 in 75% yield (43 mg). 1H NMR ([D6]DMSO, 300 MHz) [Figure
2.18] δ 10.79 (s, 1H, OH), 9.98 (s, 1H, OH), 9.48 (s, 1H, OH), 7.73 (dd, J=8.4, 2Hz, 1H),
7.69 (d, J= 2Hz, 1H), 6.98 (d, J=8.4Hz, 1H), 6.44 (d, J=2Hz, 1H), 6.19 (d, J=2Hz, 1H),
4.83 (s, 2H), 3.74 (s, 3H).

13

C NMR ([D6]DMSO, 151 MHz) [Figure 2.19] δ 175.9

(C=O), 169.4 (COO), 163.9, 160.7, 156.1, 149.2, 146.2, 145.6, 135.9, 122.6, 121.9,
116.1, 114.2, 103.0, 98.2, 93.4, 65.9 (OCH2), 51.8 (OCH3). MS (ESI) [M+Na+] m/z
397.1, HRMS (ESI) C18H14O9Na [M+Na+], calculated m/z 397.0536, found 397.0543.
Purity 97.7% (analyzed by HPLC under UV 280 nm)
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Compound 3. Two equivalents of methyl bromoacetate (0.46 g, 3.0 mmol) and
anhydrous potassium carbonate (0.42 g, 3.0 mmol) were added to a solution of compound
1 (1.0 g, 1.5 mmol) in 35 mL DMF under nitrogen. After stirring for 24 h, the resulting
mixture was worked up with 50 mL water and extracted with 100 mL EtOAc. The
organic phase was washed with water, dried over anhydrous sodium sulfate and
concentrated under reduced pressure. The red crude product was recrystallized with
EtOAc to afford 3 in 92% yield (1.0 g). 1H NMR (CDCl3, 300 MHz) [Figure 2.20] δ 7.80
(d, J=2Hz, 1H), 7.62(dd, J=9, 2Hz, 1H), 7.55-7.29 (m, 20H), 7.02 (d, J=9Hz, 1H), 6.66
(d, J=2Hz, 1H), 6.41 (d, J=2Hz, 1H), 5.30 (s, 2H), 5.17 (s, 2H), 5.14 (s, 2H), 5.02 (s, 2H),
4.89 (s, 2H), 3.80 (s, 3H). 13C NMR (CDCl3, 75MHz) [Figure 2.21] δ 174.0 (C=O), 169.0
(COO), 162.8, 159.2, 158.9, 153.5, 150.8, 148.4, 140.0, 137.3, 137.2, 137.0, 135.7,
129.2, 129.0, 128.8, 128.8, 128.7, 128.4, 128.3, 128.2, 128.1, 128.0, 127.6, 127.4, 124.0,
122.4, 115.4, 114.0, 110.3, 98.9, 95.1, 74.3, 71.3, 71.1, 70.9, 66.8 (OCH2), 52.7 (OCH3)
MS (FAB) [M+Li]+ m/z 741.5. HRMS (FAB) C46H38O9Li [M+Li+], calculated m/z
741.2676, found 741.2677.

Compound D8. Compound 3 (255 mg, 0.35 mmol) was dissolved in a minimum
amount of THF/EtOH (1:1). After addition of 10% Pd(OH)2 (38 mg), the suspension was
stirred for 16 h under one atmosphere of hydrogen from a balloon. The suspension was
filtered through Celite, diluted with EtOH and concentrated under vacuum. The residue
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was purified by recrystallization with MeOH/H2O to afford D8 as a green solid in 86%
yield (111 mg). 1H NMR ([D6]DMSO, 300 MHz) [Figure 2.22] δ 10.76 (s, 1H, OH), 9.48
(s, 1H, OH), 9.27 (s, 1H, OH), 8.75 (s, 1H, OH), 7.64 (d, J=2Hz, 1H), 7.49 (dd, J=8.5,
2Hz, 1H), 6.87 (d, J=8.5Hz, 1H), 6.51 (d, J=2Hz, 1H), 6.25 (d, J=2Hz, 1H), 4.89 (s, 2H),
3.72 (s, 3H).

13

C NMR ([D6]DMSO, 75MHz) [Figure 2.23] δ 170.8 (C=O), 168.8

(COO), 162.1, 158.6, 157.8, 147.0, 145.1, 142.1, 137.2, 122.2, 119.3, 115.7, 114.8,
105.5, 98.0, 97.6, 65.8 (OCH2), 51.8 (OCH3) MS (FAB) [M+Na]+ m/z 397.1, HRMS
(FAB) C18H14O9Na [M+Na+], calculated m/z 397.0536 found 397.0518. Purity 97.8%
(analyzed by HPLC under UV 280 nm).

Compound 6. A suspension of 5 (0.70 g, 1.50 mmol) was dissolved in 20 mL of
DMF, followed by addition of anhydrous potassium carbonate (0.311 g, 2.25 mmol) and
methyl bromoacetate (0.23 g, 1.5 mmol). The mixture was stirred overnight at room
temperature, under nitrogen. The solution was diluted with 50 mL water, acidified with
1.0 N HCl and extracted with 100 mL ethyl acetate. The organic layer was washed with
water, brine and dried over anhydrous sodium sulfate. The residue after concentration in
vacuum was purified by flash column chromatography using 5% EtOAc in DCM, to
afford 6 in 37% yield (0.30 g). 1H NMR (CDCl3, 300 MHz) [Figure 2.24] δ7.78 (dd,
J=8.5, 2Hz, 1H), 7.71 (d, J=2Hz, 1H), 7.64-7.61 (m, 4H), 7.45-7.40(m, 6H), 7.02 (d,
J=8.5Hz, 1H), 6.39 (d, J=2Hz, 1H), 6.28 (d, J=2.0Hz, 1H), 4.80 (s, 2H), 3.73 (s, 3H).
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13

C

NMR (CDCl3, 151 MHz) [Figure 2.25] δ 177.9 (C=O), 169.6 (COO), 162.4, 162.0,
156.6, 155.4, 149.5, 147.4, 139.7, 136.7, 129.3, 128.3, 126.2, 124.2, 123.8, 117.9, 108.9,
108.5, 105.6, 99.2, 93.9, 68.4 (OCH2), 52.0 (OCH3). MS (FAB) [M+Na+], m/z 561.1.
HRMS(FAB) C31H22O9Na [M+Na+], calculated m/z 561.1162, found 561.1164.

Compound D5. Compound 6 (0.30 g, 0.56 mmol) was mixed with 50 mL
CH3CO2H/H2O (4:1) and refluxed overnight. The solution is worked up by addition of
50 mL of water and then carefully neutralized by dropwise addition of saturated
NaHCO3. After the extraction with 100 mL EtOAc, the organic layer was washed with
brine, dried over anhydrous sodium sulfate and vacuum concentrated. The crude residue
was recrystallized with methanol to afford 0.156 g of D5 as a red solid in 74% yield. 1H
NMR ([D6] DMSO, 300 MHz) [Figure 2.26] δ 12.56 (s, 1H, OH), 7.60 (d, J=2Hz, 1H),
7.57 (s, 1H), 6.89 (d, J=8Hz, 1H), 6.45 (d, J=2Hz, 1H), 6.22 (d, J=2Hz, 1H), 4.68 (s, 2H).
13

C NMR ([D6]DMSO, 75 MHz) [Figure 2.27] δ 177.3 (C=O), 172.0 (CO2H), 169.8,

164.1, 161.0, 156.1, 155.1, 148.6, 145.0, 135.7, 121.0, 120.6, 115.5, 103.9, 98.5, 93.4,
67.7 (OCH2-CO2H). MS (ESI) [M+H+], m/z 361.0. HRMS (ESI) C17H13O9 [M+H+],
calculated 361.0560, found 361.0599. Purity 97.8% (analyzed by HPLC under UV 280
nm).
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Compound 8. Compound 7 (0.50 g, 0.90 mmol) in 30 mL DMF was mixed with
methyl bromoacetate (0.138 g, 0.90 mmol), followed by addition of anhydrous potassium
carbonate (0.152 g, 1.10 mmol). The mixture was stirred under nitrogen for 6 h at room
temperature and then neutralized with 1.0 N HCl. The solution was extracted with 100
mL EtOAc, washed with water, and dried over anhydrous sodium sulfate. The solvent
was removed under vacuum and the residue was flash chromatographed using
EtOAc/petroleum ether (1:1) to afford 0.360 gm of the desired product 8 in 64% yield. 1H
NMR (CDCl3, 300 MHz) [Figure 2.28] δ 12.72 (s, 1H, OH), 7.59-7.13 (m, 17H), 6.91 (d,
J=9.6Hz, 1H), 6.38 (d, J=3.9Hz, 1H), 6.34 (d, J=3.9Hz, 1H), 5.02 (s, 2H), 4.68 (s, 2H),
3.80 (s, 3H). 13C NMR (CDCl3, 75MHz) [Figure 2.29] δ 178.4 (C=O), 168.1(COO),
163.0, 161.8, 156.4, 156.2, 149.0, 147.0, 139.5, 137.0, 135.9, 129.1, 128.6, 128.1, 127.9,
126.0, 123.9, 123.8, 117.6, 108.7, 108.1, 106.2, 97.9, 92.4, 74.0, 64.7 (OCH2), 52.1
(OCH3) MS (ESI) m/z 629.2 for [M+H+], m/z 651.2 for [M+Na+], m/z 667.1 for [M+K+],
MS (FAB) [M+Na+], m/z 651.1. HRMS (ESI) C38H29O9 [M+H+], calculated m/z
629.1830, found 629.1830.
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Compound D9. Compound 8 (0.482 g) in 20 mL of EtOH/THF (1:2) was mixed
with 10% Pd(OH)2 (10 mg) and stirred overnight under hydrogen from a balloon. The
suspension was filtered through Celite and the clear green filtrate was diluted with 20 mL
EtOH and concentrated under vacuum. The residue was refluxed with acetic acid as
described in the preparation of D5 to give 0.224 g of D9 in 78% yield. 1H NMR
([D6]DMSO, 300 MHz) [Figure 2.30] δ 12.50 (s, 1H, OH), 9.67 (s, 1H, OH), 9.53 (s, 1H,
OH), 9.33 (s, 1H, OH), 7.73 (d, J=2Hz, 1H), 7.58 (dd, J=8.5, 2Hz, 1H), 6.90 (d, J=8.5Hz,
1H), 6.69 (s, 1H), 6.36 (s, 1H), 4.84 (s, 2H).

13

C NMR ([D6]DMSO, 75 MHz) [Figure

2.31] δ 175.8 (C=O), 169.5(CO2H), 163.2, 160.2, 155.7, 147.8, 147.2, 145.0, 136.0,
121.7, 120,0, 115.5, 115.1, 104.2, 97.7, 92.4, 64.8 (OCH2). MS (ESI) [M+H+], m/z 361.1.
HRMS (ESI) C17H13O9 [M+H+], calculated m/z 361.0560, found m/z 361.0555. Purity
97.7% (analyzed by HPLC under UV 280 nm).

Compound 10. Quercetin pentaacetate 9 (1.0 g, 1.95 mmol) in 50 mL dry
acetone was mixed with methyl bromoacetate (1.0 g, 6.55 mmol), anhydrous potassium
carbonate (2.0 g, 14.5 mmol) and 0.168 g potassium iodide. The suspension was refluxed
until 9 was completely consumed as judged by TLC. The suspension was filtered and the
filtrate was concentrated under vacuum, and flash chromatographed using EtOAc/Hexane
(4:3). The product was recrystallized with acetone/hexane to afford 0.577 g of 10 as a
white solid in 54% yield. 1H NMR (CDCl3, 300 MHz) [Figure 2.32] δ 7.74 (dd, J=8.5,
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2Hz, 1H), 7.70 (d, J=2Hz, 1H), 7.37 (d, J=8.5Hz, 1H), 6.83 (d, J=2Hz, 1H), 6.72 (d,
J=2Hz, 1H), 4.66 (s, 2H), 3.76 (s, 3H), 2.36 (s, 3H), 2.26 (s, 9H).

13

C NMR (CDCl3, 151

MHz) [Figure 2.33] δ 169.8 (C=O), 169.3 (COO), 168.0, 167.9, 167.8, 167.7 (4
CH3C=O), 161.8, 157.8, 153.3, 150.9, 144.2, 142.2, 133.9, 127.9, 126.4, 123.8, 123.7,
111.8, 109.0, 99.6, 65.4 (OCH2), 52.6 (OCH3), 21.0, 20.8, 20.6, 20.5 (4 CH3C=O) MS:
ESI [M+Na+] 565.1, [M+H+] 543.0, [M-CH2CO+H+] 501.1, [M-2CH2CO+H+] 459.1, [M3CH2CO+H+] 417.1 HRESI C26H22O13Na [M+Na+], calculated 565.0958, found
565.0948.

Compound D10. Twenty mg (0.036 mmol) of 10 was dissolved in 10 mL of
THF/MeOH/pH 7 phosphate buffer (9:2:9), after which 5 equivalent of N-methyl-2dimethylaminoacetohydroxamic acid (24 mg, 0.180 mmol) was added. The solution was
stirred under nitrogen atmosphere at room temperature for 12 h after which the mixture
was worked up with water, acidified to pH 6 by 1 M HCl and extracted with 50 mL of
EtOAc. The organic phase was washed with water and dried over anhydrous sodium
sulfate. The residue after concentration in vacuum was recrystallized from MeOH/H2O
to afford 11 mg of D10 as a green solid in 83% yield. 1H NMR ([D6]DMSO, 300 MHz)
[Figure 2.34] δ 9.66(s,1H), 9.53(s, 1H), 9.31(s,1H), 7.73 (d, J=2Hz, 1H), 7.57 (dd, J=8.4,
2Hz, 1H), 6.89 (d, J=8.4Hz, 1H), 6.74 (d, J=2Hz, 1H), 6.39 (d, J=2Hz, 1H), 4.97 (s, 2H),
3.73 (s, 3H).

13

C NMR ([D6]DMSO, 151MHz) [Figure 2.35] δ 176.4 (C=O), 169.0
42

(COO), 163.5, 160.8, 156.2, 148.3, 147.9, 145.5, 136.5, 122.2, 120.4, 116.0, 115.7,
104.8, 98.2, 93.0, 65.3 (OCH2), 52.4 (OCH3). MS (ESI) [M+Na]+ 397.1, HRESI
C18H14O9Na [M+Na]+, calculated 397.0536, found 397.0535. Purity 98.7% (analyzed by
HPLC under UV 280 nm).
HSP70 Inhibition Assays. Exponentially growing Jurkat cells, grown in RPMI
media with 10% fetal bovine serum, were treated with 150 uM of quercetin or its
derivatives for 1 h prior to being heated at 43 C for 30 min. The cells were allowed to
recover at 37 C for 8 h to allow for HSP70 expression and cells harvested for Western
blot analysis with mouse monoclonal antibodies against inducible HSP70 (Assay
Designs, SPA-810) and actin (ICN, clone C4). Secondary antibodies were goat antimouse conjugated horse radish peroxidase (Millipore) or alkaline phosphatase (Jackson
ImmunoResearch). Protein bands were visualized by either chemiluminescence
(SuperSignal West Femto Substrate, Thermo Scientific) or colorimetric (BCIP/NBT,
Sigma) detection.
HSP27 Phosphorylation Assays. Phosphorylation of HSP27 was detected by
Western blot analysis of total cell extracts prepared from exponentially growing HeLa
cells. Cells were grown in DMEM media with 10% calf serum and treated for 1 hr with
50 g/mL (150 µM) of quercetin or its derivatives before protein isolation. A rabbit
antibody specific for human HSP27 phosphorylated on serine 78 (Assay Designs, SPA523) coupled with goat anti-rabbit alkaline phosphatase secondary antibody (Jackson
ImmunoResearch) was utilized for colorimetric detection.
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HSF1 Electrophoretic Mobility Shift Assays (EMSA). Analysis of HSF1
interactions with the HSE DNA promoter element was carried out by EMSA essentially
as described previously [21] except that nuclear extracts (from Jurkat or Hela cells) were
utilized in place of whole cell extracts. The heat shock element probe (HSE)
d(GCGAAACTGCTGGAAGATTCCT) was 5'-32P end labeled followed by annealing to
the complementary oligonucleotide to produce the duplex DNA. Western blot analysis of
the same nuclear extracts utilized for EMSA was carried out with rabbit anti-HSF1(Cell
SignalingTechnology) followed by goat anti-rabbit HRP (Millipore) and
chemiluminescent detection.
Kinase inhibition assays. Phosphate kinases CAMKII and CK2, substrates, and
buffers were from New England BioLabs. Inhibition assays were carried out with the
PKlight HTS Protein Kinase Assay kit (Lonza) according to the manufacturer's
procedure. Briefly, this assay involves determining in triplicate the extent of
phosphorylation of a peptide substrate in the presence and absence of various
concentrations of inhibitor by quantifying the amount of ATP consumed via a luciferasebased bioluminescence assay. A kinase concentration (EC50) is used that results in 50%
consumption of ATP in the absence of inhibitor under the reaction time and conditions.
The data was then fit via non-linear least squares fitting to a standard sigmoidal doseresponse equation. CK2 inhibition assay: Casein Kinase II (CK2) was incubated at 30
C for 30 min with 300 M substrate (RRRADDSDDDDD), 100 M ATP, in a buffer
containing 20 mM Tris-HCl, 50 mM KCl, 10 mM MgCl2, with or without the presence of
inhibitor. CamKII inhibition assay: Ca2+/Calmodulin-Dependent Protein Kinase II
(CaMKII) supplemented with 200 µM ATP, 1.2 µM calmodulin and 2 mM CaCl2 was
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incubated for 10 min at 30 °C to preactivate the enzyme and then diluted to the required
concentration. The activated CaMKII was then incubated at 30°C for 30 min with or
without the inhibitor, along with 300 M autocamtide-2 (KKALRRQETVDAL), 100 M
ATP, in a buffer containing 50 mM Tris-HCl, 10 mM MgCl2, 2 mM DTT, 0.1 mM
Na2EDTA at pH 7.5.
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Table 1. Quercetin derivatives. The substituent is an H unless otherwise noted.
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+++

CK2

Table 2.

IC50 values (M) for inhibition of CK2 and CamKII by quercetin and derivatives
D1-D10.
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Figure 2.1

Schematic of the pathway for heat shock induction of HSP70 expression.
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Figure 2.2 Two known inhibitors of heat induced HSP70 expression.
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Figure 2.3 Scheme of the synthesis of quercetin mono-methyl derivatives (D6, D2) based on published procedure [20].
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Figure 2.10 Effect of quercetin and its derivatives on heat induced HSP70 expression and
phosphorylation of HSP27. Panel A. Inhibition of heat induced HSP70 expression. Jurkat cells
pre-treated 1 h with 50 g/mL (approx. 150 M) of the quercetin derivatives D1-D10 were heat
shocked as indicated then allowed to recover at 37 C for 8 h before protein isolation and
analysis. HSP70 and actin protein levels were determined by Western blotting: Lane C: nonheated cells; N: heated no drug; D1-D10, quercetin derivatives. Panel B. Drug induced
phosphorylation of human HSP27 Ser78. HeLa cells were treated for 1 h with drug (50 g/mL,
approx. 150 M) before cellular proteins were isolated for Western blot analysis with actin and
HSP27 Ser78P antibodies: Lane C: no drug; V: DMSO vehicle only; Q: quercetin; D1-D10:
quercetin derivatives.
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Figure 2.11 Effect of quercetin on HSF1 binding to HSE DNA. Jurkat (Panel A-upper) or HeLa
cells (Panel A-lower) were heated or pre-treated with quercetin (50 g/mL, approx. 150 M) 1 h
prior to heating and allowed to recover at 37 C for 0-8 h at 37 C. Cells were isolated and
nuclear extracts prepared for EMSA analysis with a 5’-radiolabeled HSE oligodeoxynucleotide.
Position of the HSF1-HSE complex is indicated by the arrows. Lane O: HSE oligonucleotide
without extract; C: unheated extract; Q: quercetin treated, no heat. HSF1 content of EMSA
nuclear extracts (Panel B). Nuclear extracts utilized in Panel A were subjected to Western blot
analysis with anti-HSF1 antibody to determine the HSF1 levels and relative size. Lane C: nuclear
extract from unheated cells; Q: quercetin treated for 2.5 h; HS: 1 h after a 43 C/30 min heat
shock; HS+Q: 1 h quercetin treatment, 43 C/30 min heat shock and 1 h recovery.
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Figure 2.12 1H NMR ([D6]DMSO, 300 MHz) spectrum of compound D6.
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Figure 2.13 1H NMR ([D6]DMSO, 300 MHz) spectrum of compound D1.
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Figure 2.14 1H NMR ([D6]DMSO, 300 MHz) spectrum of compound D3.
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Figure 2.15 1H NMR ([D6]DMSO, 300 MHz) spectrum of compound D7.
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Figure 2.16 1H NMR (CDCl3, 300 MHz) spectrum of compound 4.
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Figure 2.17

13

C NMR (CDCl3, 75 MHz) spectrum of compound 4.
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Figure 2.18 1H NMR ([D6]DMSO, 300 MHz) spectrum of compound D1.
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Figure 2.19

13

C NMR ([D6]DMSO, 151 MHz) spectrum of compound D1.
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Figure 2.20 1H NMR (CDCl3, 300 MHz) spectrum of compound 3.
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Figure 2.21

13

C NMR (CDCl3, 75 MHz) spectrum of compound 3.
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Figure 2.22 1H NMR ([D6]DMSO, 300 MHz) spectrum of compound D8.
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Figure 2.23

13

C NMR ([D6]DMSO, 75 MHz) spectrum of compound D8.
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Figure 2.24 1H NMR (CDCl3, 300 MHz) spectrum of compound 6.
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Figure 2.25

13

C NMR (CDCl3, 151 MHz) spectrum of compound 6.
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Figure 2.26 1H NMR ([D6]DMSO, 300 MHz) spectrum of compound D5.
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Figure 2.27

13

C NMR ([D6]DMSO, 75 MHz) spectrum of compound D5.
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Figure 2.28

1

H NMR (CDCl3, 300 MHz) spectrum of compound 8.
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Figure 2.29

13

C NMR (CDCl3, 75 MHz) spectrum of compound 8.
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Figure 2.30 1H NMR ([D6]DMSO, 300 MHz) spectrum of compound D9.
79

HO2C

OH
O

O

OH O

OH
OH

D9

Figure 2.31

13

C NMR ([D6]DMSO, 75 MHz) spectrum of compound D9.
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Figure 2.32 1H NMR (CDCl3, 300 MHz) spectrum of compound 10.
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Figure 2.33

13

C NMR (CDCl3, 151 MHz) spectrum of compound 10.
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Figure 2.34 1H NMR ([D6]DMSO, 300 MHz) spectrum of compound D10.
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Figure 2.35

13

C NMR ([D6]DMSO, 151 MHz) spectrum of compound D10.
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Chapter 3.
Identification of Quercetin Binding Proteins with a
Biotinylated Quercetin Photoaffinity Reagent

The text of this chapter was taken in part from a manuscript coauthored with Clayton R.
Hunt, Jiawei Chen, and John-Stephen Taylor (Washington University)
Rongsheng E.Wang, Clayton R. Hunt, Jiawei Chen, John-Stephen Taylor (Manuscript
submitted, 2010)
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Abstract
Quercetin is a naturally occurring flavonoid natural product that is found in many foods
and has been found to have a wide range of medicinal effects. Though a number of
quercetin target proteins have been identified, there has been no systematic approach to
identifying all potential targets of quercetin. We are describing an O7- biotinylated
derivative of quercetin (BioQ) that can act as a photoaffinity proteomics reagent for
capturing quercetin target proteins, which can then be identified by LC MS/MS. BioQ
was shown to inhibit heat induction of HSP70 with almost the same efficiency as
quercetin, and to inhibit and photocrosslink to CK2 kinase, a known target of quercetin
involved in activation of the heat shock transcription factor. When normal or heat
shocked Jurkat cells were incubated with BioQ, then UV-irradiated before being lysed, a
number of proteins could be recovered by subsequent incubation with streptavidin beads.
Following gel electrophoresis, isolated protein bands were trypsinized and analyzed by
LC MS/MS to identify heat shock proteins HSP70 and HSP90 as potential targets, along
with ubiquitin-activating enzyme, a spliceosomal protein, mitochondrial and RuvB-like 2
ATPases, and eukaryotic translation initiation factor 3. Most of these proteins have been
previously identified as potential therapeutic targets for cancer, suggesting that some of
the anticancer properties of quercetin may be related to their inhibition.
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Introduction
Quercetin has antioxidant [1, 2], anti-inflammatory[3] and anticancer [4-6] activities
with almost no human toxicity [7]. At the molecular level, quercetin has been found to
inhibit many ATP binding enzymes and in particular kinases [8], suggesting that some of
its biological effects may be due to inhibition of signaling pathways. Thus quercetin is an
interesting lead compound for further pharmaceutical development [5] and has been the
subject of over 7,000 research publications. In spite of this, very little is known about all
the proteins it targets and which are predominantly responsible for a particular biological
effect.
As introduced in chapter 1, our interest in quercetin initially arose from its well
known ability to inhibit the heat induction of heat shock protein 70 (HSP70), also known
as HSP70-1a, HSP70-1 and HSP72. The HSP70 deficient mouse embryonic fibroblasts
are more sensitive to radiation following heat treatment [9] suggesting that agents that
suppress heat induction of HSP70 might function as radiosensitizers. Despite the
classification as a heat responsive protein, HSP70 is also induced, along with other heat
shock proteins, in response to wide range of chemical and physiological stresses, and is
overexpressed in many cancers [10-12]. Thus small molecule inhibitors of HSP70 and its
induction may have potential therapeutic value for treating cancer. Unfortunately,
quercetin's multiple biological effects and the high concentration required to inhibit
HSP70 induction diminish its potential as a therapeutic adjuvant.
Identifying the protein target(s) of quercetin's inhibition of HSP70 and its induction,
however, could aid in the development of more selective agents. One systematic
approach has involved screening chromatographic fractions of cells extracts for
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quenching of protein fluorescence in the presence of quercetin, followed by SDS-PAGE
of the active fractions, and MASCOT analysis of the trypsinized fragments [13].
Unfortunately, without authentic protein samples, it is difficult to establish which of the
protein bands detected in the SDS-PAGE gel are quercetin binding proteins.
A more promising method for identifying protein targets of a bioactive compound
is to derivatize the compound with biotin which serves as an affinity tag allowing the
bound proteins to be isolated with streptavidin [14, 15]. The isolated proteins are then
separated and identified by bottom up mass spectrometry. There have been several
reports in which compounds with Kd's of around 1 nM can be isolated in this manner
from cell lysates [16-18]. To identify more weakly binding proteins, phage display
libraries have been used in place of cell lysates to afford a higher concentration of protein
[19], although this approach is limited by the contents of the library. Another approach is
to increase the affinity of the compound by attaching a photocrosslinking agent [14, 15,
20] or by making use of intrinsic photoaffinity properties of the compound. In all cases,
biotin must be attached to the compound at a position that does not interfere with target
protein binding.
In chapter 2, to guide the synthesis of biotinylated quercetin derivatives, we
synthesized all of the mono-methyl and selected carbomethoxymethyl derivatives of
quercetin and determined their ability to inhibit heat shock induction of HSP70s [21].
We found that the C7 and C3' hydroxyls on quercetin can be derivatized with a bulky
carbomethoxymethyl group without affecting its ability to inhibit HSP70 induction, and
could therefore be used to attach biotin (Figure 3.1). We also found that all quercetin
derivatives capable of inhibiting heat induction of HSP70, were also able to inhibit two
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protein kinases known to activate heat shock transcription factor 1 (HSF1), CAMK2 and
CK2, suggesting that these may be targets of quercetin’s action. The Kd's for these
enzymes, and for most known enzyme targets of quercetin are in the micromolar range,
indicating that a photoaffinity approach would be required to pull down the quercetin
binding proteins. Luckily, quercetin has been shown to be photoactive [22], and to
photocrosslink malate dehydrogenase to which it binds [23]. In this chapter, I am
presenting the synthesis of the C7-biotinylated quercetin derivative, 7-BioQ, and show
that it can be photocrosslinked to CK2 in vitro, and to various proteins in vivo following
heat shock, among which were heat shock protein 70 and 90, two ATPases, an ubiquitin
activating protein, and a translation initiation factor. Most of these proteins have been
previously identified as potential therapeutic targets for cancer, suggesting that their
inhibition may also be partially responsible for the anticancer effects of quercetin.

Results
Synthesis of the Biotin Quercetin Conjugate, BioQ. The selective coupling of
biotin to the 7-OH of quercetin was carried out by two synthetic routes (Figure 3.2) based
on a previously developed method for the selective methylation and benzylation of the 7OH [27]. The first route was to alkylate the 7-OH with tert-butylchloroacetate after
which the ester would be converted to an acid and coupled to an amine derivative of
biotin. Thus, quercetin pentaacetate was refluxed in anhydrous acetone with excess tertbutyl chloroacetate in the presence of potassium carbonate and catalytic potassium iodide
with TLC monitoring to minimize over-alkylation. The tert-butyl ester 2 was converted
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to the acid 3 by treatment with 20 % trifluoroacetic acid in methylene chloride under
anhydrous conditions to limit competing hydrolysis of the remaining acetate protecting
groups. Coupling of the amino biotin derivative 6 [26] with the tetra-acetate acid 3 was
problematic. Both reactants are very polar and only dissolved well in dimethyl
formamide or water-acetonitrile mixtures. When the reaction was carried out in the
presence of N, N-diisopropylethylamine (DIPEA) with HATU, DCC, or ByBOP,
extensive decomposition of the quercetin tetra-acetate occurred, which may have been the
result of deacetylation. Similar results were observed with DCC or EDC in dimethyl
formamide in the absence of base, suggesting the possible involvement of the amino
group of amino biotin 6 and hence the necessity of a buffered solution in neutral to acidic
pH. Final treatment with EDC and N-hydroxysuccinamide at a slightly acidic pH of 6, in
the presence of MES buffer, afforded the desired coupled product 5 in 10 % to 15 %
yield. Attempts to improve the yield by further lowering the pH, however, failed to give
desired product. Complete deacetylation was attempted under basic conditions, such as
aqueous sodium hydroxide or sodium methoxide in methanol, but only afforded the
desired biotinylated quercetin 9 in low yield. Biotinylated quercetin could be obtained,
however, in 74% yield upon treatment with the hydroxamic acid 8 under near neutral
conditions in pH 7.4 phosphate buffer.
Because direct coupling of the quercetin acid 3 with biotin amine 6 was so
problematic we investigated whether we could directly alkylate the 7-OH of quercetin
with the commercially available biotin alkylator –biotin(PEO) iodoacetamide 7. Ideally,
one could simply use the method described above in which quercetin penta-acetate is
alkylated selectively at O7 by refluxing the alkylating agent with potassium carbonate in
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acetone. We were, however, concerned that the iodine containing 7 might self-react
under these conditions, so we decided instead to alkylate the quercetin tetraacetate 4
under milder conditions. Quercetin tetra-acetate 4 has been previously prepared by
treatment of the penta-acetate 1 with lipase [28], or more recently, with imidazole and
thiophenol in N-methyl-2-pyrrolidone (NMP) [29]. We found that the latter method
using the more convenient solvent dichloromethane in place of NMP afforded quercetin
tetra-acetate 4 in 65% yield (Figure 3.2). Treatment of 4 with the iodoacetamide 7 in
anhydrous dimethyl formamide with cesium carbonate in the dark afforded the desired
biotinylated quercetin tetra-acetate 5 in 85% yield. Attempts to use potassium carbonate,
in place of cesium carbonate, failed to give the desired product. Deacetylation of
compound 5 with N-methyl-2-dimethylamino-acetohydroxamic acid again afforded
biotinylated quercetin 9.
Structural Characterization of BioQ 9. To verify that the biotin was indeed
coupled to the hydroxyl at position 7 of quercetin, and had not been coupled to another
hydroxyl that might have been produced by transesterification of the acetate groups, we
characterized the product by COSY, HMQC, and HMBC NMR (Figures 3.3-3.6).
Aromatic protons H15 and 16 could be readily identified by their large ortho-coupling in
the 1D 1H NMR and a strong crosspeak B in the COSY spectrum (Figure 3.4). This
allowed identification of proton 12 through a crosspeak A with H16, leaving aromatic
protons H6 and H8 which showed a crosspeak C between them. The assignment of
protons H6 and H8 allowed identification of C7 in the HMBC spectrum through
crosspeaks J and H (Figure 3.6). C7 in turn showed a crosspeak F to the H17 protons of
the acetamide group verifying the connection of the biotin derivative to O7. The
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assignment of the H17 protons was confirmed by a crosspeak E with C18 via HMBC,
which in turn showed a correlation K with the amide NH (d) (Figure 3.6). The biotin
group could be easily identified by the crosspeak (D) between H19 and H20 (Figure 3.4).
The rest of structure could be confirmed by key proton-carbon crosspeaks in the HMBC
spectrum (Figure 3.6), such as crosspeaks G (Hb - C21), Q (Ha – C21), I (H6 – C5), L (H8
– C9), M (H15 – C14), N (H16 – C11), O (H12 – C11) and P (H12 – C14).
Substrate activities of BioQ. Previously, we had shown that quercetin and its 7-Omethyl and carbomethoxymethyl derivatives could inhibit Casein kinase II (CK2) and
Ca2+/calmodulin-dependent protein kinase II (CAMK2), and that this inhibition was
correlated to its ability to inhibit heat induction of HSP70s [21]. To determine whether
derivatization of quercetin at O7 with a much larger biotin-containing group would
interfere with binding to these enzymes, the ability of BioQ to inhibit these enzymes was
assayed by the same in vitro protein kinase inhibition assay we used previously for the
simple quercetin derivatives (Table 1). The IC50s of both quercetin and BioQ for CK2
were similar and about 5 M, while the IC50 of BioQ for CAMK2 was about 8-fold
higher than for quercetin (25 M compared to 3 M). To determine whether BioQ could
inhibit heat induction of HSP70s, Jurkat cells, which have a very low basal expression of
HSP70s, were heat shocked in the presence of 145 M quercetin and BioQ, and assayed
by a western blot. BioQ showed substantial inhibition of HSP70 induction compared to
the controls, though not as complete as quercetin (Figure 3.7). The lower inhibition of
HSP70 induction by BioQ is consistent with a higher IC50 for CAMK2 than observed for
quercetin, and my previous conclusion that effective inhibitors had to be good inhibitors
of both CK2 and CAMK2 [21]. It may also be that BioQ is not as permeable as quercetin
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and unable to achieve a high enough concentration in the cell to be completely effective
against CAMK2, which required an IC50 of 25 M. None-the-less, the ability of BioQ to
cause substantial inhibition of heat shock induction of HSP70 validated its use as an
affinity probe for proteins involved in this and possibly other biological process. In this
regard, other 7-O-quercetin derivatives have been shown to retain antitumor activity [30].
Casein kinase 2 pull-down in vitro by BioQ probe. Our attention then focused on
demonstrating that I could pull down casein kinase 2 (CK2) which we had demonstrated
could be inhibited by the BioQ probe. Initial experiments indicated that the streptavidin
agarose beads would also bind and pull down proteins in the absence of BioQ when using
the same buffer that would be used to lyse the cells. Despite many attempts, I was
unsuccessful at finding a wash buffer that would remove non-specifically bound proteins
from the streptavidin beads without removing BioQ bound proteins.
Because quercetin has been reported to be photoreactive and capable of
photocrosslinking to malate dehydrogenase [23], we thought that UV irradiation could be
used to photocrosslink BioQ to CK2 and other target proteins in vivo. Photocrosslinking
would thus prevent CK2 or other target proteins from dissociating during affinity
purification with the streptavidin and allow more stringent washing steps. Quercetin and
BioQ show two absorption maxima at about 320 and 380 nm of about equal absorptivity,
the latter of which would be preferred for photocrosslinking in vivo. Irradiation of
quercetin and BioQ in 10 mM pH 7.2 PBS buffer with Woods glass filtered medium
pressure mercury arc lamp which passes light from 320-400 nm, and has a peak intensity
at 365 nm, led to the irreversible bleaching of the longer wavelength absorption
maximum for quercetin within 10 min, and both wavelength maxima for BioQ within 30
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min (Figure 3.8). No bleaching was observed, however, in Tris buffer, possibly due
radical quenching by the buffer [31].
In a model study an equimolar mixture of DRVYIHPFHL (angiotensin I)
RPKPQFFGLM (substance P) was irradiated with 4 mM of BioQ. Analysis by LC
MS/MS showed the formation of an adduct between angiotensin I and a biotin-containing
fragment of BioQ (Figure 3.9), demonstrating BioQ’s ability to photocrosslink to a
protein target. The quercetin portion of the biotin fragment detected has been previously
identified in the photolysis of quercetin [22, 23].
To verify the ability of BioQ to photocrosslink to a target protein, I incubated
increasing concentrations of CK2 (from 1 g to 4 g) with BioQ in 400 µL 10 mM PBS
buffer (pH 7.2) with and without irradiation for 30 min with Woods glass filtered medium
pressure mercury arc lamp. The mixture was then incubated with streptavidin beads,
followed by centrifugation and washing of the beads to remove non-specifically bound
protein. CK2 is a tetramer consisting of two 45 kDa α-subunits and two 25 kDa βsubunits which can be readily detected as two discreet bands on an SDS-PAGE gel. The
SDS-PAGE analysis, however, did not detect any photo-crosslinked CK2 by silver
staining (Figure 3.10a). As Casein kinase II is an ATP dependent kinase that is known to
autophosphorylate, it was possible that autophosphorylation was required for CK2 to bind
to quercetin. We therefore incubated CK2 and BioQ in the presence of 2 M ATP in
PBS buffer for 30 min, after which some samples were additionally photoirradiated for
30 min prior to analysis by SDS-PAGE. After much experimentation, we found that a
2% SDS Tris-HCl buffer was sufficient to remove non-specifically bound proteins from
the streptavidin agarose beads, without denaturing the streptavidin and causing the
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release of the biotinylated CK2. Analysis of SDS-PAGE (Figure 3.10b) showed that a
significant amount of both α and β subunits appeared in lane 6 once the concentration of
CK2 reached 4 g/400 L (70 nM).
BioQ protein pull down from cells. Having verified that photoirradiated BioQ
could pull down a known quercetin binding protein, we carried out pull down
experiments with cells that had been incubated with BioQ. In one set of experiments the
photocrosslinking step was carried out after cell lysis (Figure 3.12), and in a second set
before cell lysis (Figure 3.13). As can be seen from lanes 1-4 of the 12% SDS PAGE gel
shown in Figure 3.12, a large number of proteins were pulled down by the streptavidin
beads in the absence of a denaturing wash whether incubated with BioQ and/or heat
shock. With the exception of contaminating keratin proteins, the high protein
background was reduced considerably with a denaturing wash as shown in lane 7 for cells
that were incubated with BioQ and heat shocked. When cell lysates that had been
incubated with BioQ with or without heat shock were also UV irradiated for 30 min prior
and subjected to a denaturing wash following pull-down with the streptavidin beads,
discrete new bands A-F were observed (lanes 5 & 6). Similar results were obtained when
the cells were irradiated prior to lysis (Figure 3.13).
To confirm that the proteins appearing in the gel had been photomodified with
BioQ, a western blot with a biotin-specific antibody was carried out (Figure 3.12, lane 810, Figure 3.13, 9-14). Samples for lanes 8-10 of Figure 3.12 were identically prepared,
except that sample for lane 8 was not UV irradiated and the sample for lane 10 lacked
BioQ, and neither showed any band with the anti-biotin antibody. Lane 9, however,
clearly showed several bands that corresponded to the major bands observed in the silver
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stained gel. Likewise, lane 12 of Figure 3.13 in which the heat shocked cells had been
irradiated prior to lysis and followed by a standard wash showed the presence of
significant amounts of biotinylated proteins.
Mass spectrometric identification of proteins pulled down in vivo. Proteins
contained in discrete bands A to F of the gel in Figure 3.13 that were confirmed to be
biotinylated (lane 12) were isolated, trypsinized and analyzed by LC-MS/MS.
Corresponding sections of a control lane were similarly analyzed so that contaminating
proteins such as keratins and albumins could be excluded. Mascot search [32] of the
NCBI database led to the identification of candidate target proteins shown in Table 2.
For each band only candidates with the highest probability are listed. In the case of band
A, it appeared that two proteins were present, ubiquitin activating enzyme E1 (MW 118
kD) and spliceosomal protein SAP 130 (MW 137 kD) had similar scores, which also
closely matched the apparent MW of about 110 kD. Likewise, for band D, two proteins
were detected, RuvB-like 2 (MW 51 kD) and mitochondrial ATP synthase (MW 56 kD)
which scored similarly, and closely matched the apparent molecular weight of 50 kD.
Heat shock protein 90 (MW 98 kD), was identified as the only protein identified in band
B which migrated with an apparent weight of about 100 kD. Likewise, band C was a
good match for HSP 70 and band E most closely matched eukaryotic translation initiation
factor 3.

Discussion
The strategy for coupling photoaffinity and affinity purification agents to a
biologically active ligand to facilitate isolation of a target protein is a powerful approach
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to identifying potential therapeutic targets [14, 15, 20]. The general idea appears to have
been first described over 20 years ago for the isolation of ACTH receptors, [33] and
successfully implemented a few years later for isolation of a melanocyte-stimulating
hormone receptor [34]. In both cases, biotin had been selected as the affinity purification
agent because of its high affinity for streptavidin, which in principal would enable facile
separation of a protein bearing a biotinylated ligand from non-target proteins. In practice,
however, it was difficult to find conditions that would reduce the non-specific binding of
the proteins to the streptavidin without dissociating the biotinylated ligand protein
complex. We also found this to be the case for the biotinylated quercetin affinity probe.
This led to the idea of using a photoaffinity crosslinker to covalently link the biotinylated
ligand to the target protein, and permit the use of more stringent wash conditions.
In our case, quercetin was known to have intrinsic photoreactivity, and reported to
crosslink to malate dehydrogenase [23], thereby only necessitating the attachment of the
biotin to create a pull down probe. We had already determined that the O7-position of
quercetin did not interfere with the ability of quercetin to inhibit HSP70 induction in
vivo, or to inhibit two of the presumed target proteins CK2 and CAMK2, and so this site
was chosen for biotinylation [21]. As we had found for a simpler derivative, quercetin
biotinylated at the O7 position retained its ability to penetrate cells and inhibit heat shock
induction of HSP70 (Figure 3.7) and inhibit the putative kinase targets involved (Table
1). Initial attempts to demonstrate photocrosslinking of BioQ to BSA or malate
dehydrogenase however failed, possibly because the derivatization of the O7 position
interfered with binding to these proteins. We did confirm, however, that the BioQ was
photoreactive, and could be photobleached by irradiation with a UVA light source
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(Figure 3.8). In a very limited study in collaboration with Jiawei Chen, I found that
irradiation of BioQ with angiotensin I resulted in an adduct of the peptide (Figure 3.9).
We therefore turned to CK2 kinase as a model target, which we showed was
inhibited by BioQ, but initially did not show any photocrosslinking with BioQ. The
inhibition assay was conducted in the presence of ATP and a peptide substrate, but the
initial photocrosslinking experiments were carried out in the absence of ATP. When
ATP was added, however, photocrosslinking took place, suggesting that CK2, which is
known to autophosphorylate [35], must be in its phosphorylated state to bind quercetin.
Further experiments established that ATP was consumed by CK2 in the presence of
quercetin and the absence of substrate (Figure 3.11). This suggests that quercetin may be
binding to a site other than the ATP binding pocket, such as the allosteric cleft between
α/β surface of CK2 [36], where the interaction of α, β subunits is believed crucial to the
function of CK2 kinase. In accord with this idea, BioQ pulled down both subunits,
though it appeared to have a higher affinity for the β subunit (Figure 3.10).
BioQ was also able to specifically pull down target proteins from normal and heatshocked cells as shown in Figure 3.12 using a photocrosslinking step that followed cell
lysis and a stringent wash step. In the absence of the stringent wash step many nonspecifically bound proteins were also eluted from the streptavidin beads (Figure 3.12,
lanes 1-4). In the presence of a stringent wash step, and the absence of a
photocrosslinking step, no distinct protein bands were observed other than what could be
attributed to contaminating keratin proteins (Figure 3.12, lane 7). Only in the presence of
the stringent wash step and photocrosslinking could discrete proteins be observed (lanes 5
& 6) that could be detected by a biotin antibody (Figure 3.12, lane 9). Similar results
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were observed for the pull down experiment in which photocrosslinking was carried out
prior to cell lysis.
Protein identification was only carried out on the sample of cells that were heat
shocked and then irradiated prior to lysis (Figure 3.13), in order to obtain sufficient
protein for analysis and to avoid artifacts that may result from irradiating the cells
following lysis. Analysis of the protein bands by LC MS/MS indentified ubiquitinactivating enzyme E1 (UBA1), splicesomal protein (SAP130), heat shock proteins 90 and
70-2 (HSP90AA1, HSPA2), RuvB-like 2 (RUVBL2) helicase and mitochondrial ATP
synthase (ATP5B) ATPases, and eukaryotic translation initiation factor 3 (SF3B3), as
possible targets of quercetin (Table 2). Five of these proteins have known or putative
ATP binding domains (UBA1, HSP90AA1, HSPA2, RUVBL2 and ATP5B), which is in
accord with quercetin’s known ability to inhibit ATPases and kinases. The remaining
two proteins, SF3B3, EIF3F are not associated with nucleotide binding domains, and may
bind through some other site. Quercetin has previously been shown to bind to
mitochondrial ATP synthase between the  and  subunits and thereby inhibit ATPase
activity [37]. ATP synthetase has been found to be upregulated in breast cancer, and the
ATP synthetase inhibitor aurovertin B is being investigated as a therapeutic agent [38].
RuvB-like 2, is also an ATPase as well as a putative helicase that has been found to be
overexpressed in hepatocellular carcinoma and required for cell viability [39].
Both splicesomal protein (SAP130) and eukaryotic translation initiation factor 3
which we identified as targets of quercetin are important in translation or post-translation
protein synthesis steps [40, 41]. As such, these proteins may play a role in the expression
of inducible heat shock proteins 70-1 and 90 [42], which quercetin is known to inhibit
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[43]. The spliceosome is a known target of some anticancer compounds [44], while the
eukaryotic initiation factor has been found to be upregulated in breast and prostate
cancer, and thus represents a new therapeutic target [40, 45]. Our observation that
quercetin binds to constitutively expressed HSP70-2 and HSP90 could also explain the
decreasing level of these proteins in quercetin treated cells [46, 47], which might result
from the deactivation of these proteins and their subsequent degradation or aggregation in
the cell. Both HSP70 and HSP90 proteins are of current interest as anticancer targets
[48-51].
Another potential target of quercetin that we identified was the ubiquitin-activating
enzyme E1 which initiates protein degradation through the E1-E2-E3 mediated
proteosome pathway [52]. Binding to this enzyme could explain the observation that
quercetin inhibits the ubiquitin-protesome pathway for degradation of unfolded proteins
[53]. Currently, ubiquitin-activating enzyme E1 is being investigated as a therapeutic
target for treatment of leukemia and multiple myeloma [54]. Inhibition of the
proteosome pathway, together with the heat shock protein pathway for repairing unfolded
proteins could induce cell apoptosis, which may be one of the mechanisms behind the
anti-tumor activity of quercetin.

Conclusion
We have shown that biotin linked to the 7-hydroxyl of quercetin, BioQ, can be used
as a photoaffinity agent to isolate quercetin binding/target proteins from cells which can
then be identified by bottom up mass spectrometry. Many of the proteins identified as
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targets of quercetin have also been found to be potential therapeutic targets for cancer,
and all might play a role in the apoptotic and anti-tumor activities of quercetin. It is
conceivable that the anticancer activity of quercetin is due to simultaneous but low level
inhibition of multiple therapeutic targets, which might explain how a molecule with low
specificity and toxicity can achieve a positive therapeutic effect.
The site for attaching biotin to quercetin was originally chosen because it did not
substantially interfere with quercetin inhibition of heat induced HSP70 induction or the
inhibition of CK2 and CAMK2 kinase activity, which are thought to be involved in heat
shock transcription factor activation. Surprisingly, neither of these kinases was detected
in the assay, possibly because they were only present at much lower levels than the other
proteins. In this case, screening against a phage display library of proteins might prove to
be more advantageous [19]. A phage display library could also provide the means and
sufficient sensitivity to identify the preferred peptide binding sites for interaction with
quercetin.
Though we have identified a number of possible quercetin targets, it is also likely,
that a number of targets were not pulled down by the BioQ probe, either because the
position of the biotin interfered with binding, or because of an inefficient
photocrosslinking reaction. The mechanism and amino acid specificity of the
photocrosslinking reaction has yet to be investigated. To screen for all the possible
targets of quercetin, it might be necessary to attach biotin along with an additional
photocrosslinking agent to other positions of quercetin. In any case, this approach
appears to be a fruitful one for beginning to unravel the biomolecular basis for the
medicinal effects of a ubiquitous natural product in our diet.
101

Experimental Section
Abbreviations
ATP: adenosine triphosphate; HSP70: heat shock protein 70; SDS: sodium dodecyl
sulfate; PAGE: polyacrylamide gel electrophoresis; Kd: dissociation constant;
CAMK2: Calcium/calmodulin dependent protein kinase II; CK2: casein kinase 2; BioQ:
Biotin conjugated quercetin (conjugation at position 7); UV: ultra violet; NMR: nuclear
magnetic resonance; COSY: homonuclear correlation spectroscopy; HMBC:
heteronuclear multiple bond correlation; HMQC: heteronuclear multiple quantum
correlation; TLC: thin layer chromatography; HCl: hydrochloric acid; MES: 2-(Nmorpholino)ethanesulfonic acid; DMSO: dimethyl sulfoxide; HPLC: high pressure
liquid chromatography; Tris: Tris(hydroxylmethyl)aminomethane; EDTA: ethylene
diamine tetraacetic acid; BSA: bovine serum albumin; HRP: horseradish peroxidase;
LTQ: linear trap quadruple; NCBI: national center for biotechnology information;
HATU: 2-(1H-7-Azabenzotriazol-1-yl)--1,1,3,3-tetramethyl uronium
hexafluorophosphate Methanaminium; DCC: dicyclohexyl carbodiimide; EDC: 1-ethyl3-(3-dimethylaminopropyl) carbodiimide; PyBOP: benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate; NMP: N-methyl-2-pyrrolidone;
IC50: concentration of 50% inhibition; LC MS/MS: liquid chromatography-tandem mass
spectrometry; UBA1: ubiquitin-activating enzyme E1; SAP130: splicesomal protein
130; HSP90: heat shock protein 90; HSPA2: heat shock protein 70-2; RUVBL2: RuvBlike 2; ATP5B: mitochondrial ATP synthase; EIF3F: eukaryotic translation initiation
factor 3.
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General procedures
Anhydrous dimethyl formamide and acetone were from EMD chemicals Inc.
Anhydrous dichloromethane was freshly prepared by refluxing with calcium hydride
followed by distillation. All other reagents were directly purchased from Omni Solvent
or Sigma Aldrich unless otherwise specified. Analytical thin-layer chromatography was
performed on Aldrich Silica gel 60 F254 plates (0.25 mm). Compounds were visualized
by UVG-54 mineral light UV lamp at 254 nm. Flash column chromatography was
conducted using the indicated solvent on E. Merck silica gel 60 (40-63 m). 1H NMR and
13

C NMR spectra were carried out on Varian Mercury-300 MHz, 500 MHz or 600 MHz

spectrometers. UV-Vis full spectra were obtained on a Varian Cary 100 UV Bio UVVisible spectrophotometer. High capacity streptavidin agarose resin, Silver SNAP stain
kit and Avidin conjugated horseradish peroxidase was from Pierce Thermo Fisher
Scientific Inc, and the Western blot kit was from Bio-Rad Laboratories. ECL staining
reagents as well as mouse anti-actin antibody and horseradish peroxidase conjugated antimouse secondary antibody were from GE Healthcare Systems. Silver staining was
carried out by a standard protocol [24] or with the Pierce Silver Stain Kit (Pierce).
Protease inhibitor cocktail tablets were from Roche Pharmaceuticals. 1H NMR, 13C
NMR were recorded with Mercury-300, Inova-500 and Inova-600 (Varian Assoc., CA)
instruments while 2D NMR were recorded with Inova-600 spectrometer. All the data
were processed with VNMR series software (Varian Assoc., CA) with standard functions
and the chemical shifts were referenced by TMS standard. Proton spectra were collected
in around 8000 Hz spectral width and 32K data points. Carbon spectra were collected in
30000 Hz spectral width and 64 K data points. The COSY experiments were obtained
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with 512 real points in the F1 dimension and 2000 complex points in the F2 dimension.
HMBC (Heteronuclear Multiple Bond Correlation) were collected with 10.2 seconds 90o
1

H pulse width and 14.0 seconds 90o 13C pulse width. HMQC (Heteronuclear Multiple

Quantum Correlation) were recorded using a 0.3 s H-13C nulling period, with other
parameters exactly the same as they are in HMBC.

7-O-carbo-ter-butoxymethyl-quercetin tetraacetate 2

Quercetin pentaacetate 1 (1.0 g, 1.95 mmol) [25] was dissolved together with tert-butyl
chloroacetate (3.0 g, 19.5 mmol) in 50 mL anhydrous acetone, followed by the addition
of anhydrous potassium carbonate (2.0 g, 15 mmol) and potassium iodide (0.166 g, 1
mmol). The suspension was refluxed for two hours at which point TLC indicated the
reaction was near completion. The reaction mixture was filtered to give a yellowish clear
solution, concentrated in a rotatory evaporator and the residue purified by flash column
chromatography (ethyl acetate/hexane 4:3) to give a solid that was recrystallized with
acetone/hexane to give white solid 2 in 65 % yield (0.66 g, 1.27 mmol) [Figure 3.12].
1

H NMR (300 MHz, CDCl3) [Figure 3.16] δ 7.69 (dd, J=8.0, 2.0Hz, 1H), 7.66 (d,

J=2.0Hz, 1H), 7.34 (d, J=8.0Hz, 1H), 6.80 (d, J=2.0Hz, 1H), 6.67 (d, J=2.0Hz, 1H), 4.60
(s, 2H), 2.42 (s, 3H), 2.33 (s, 9H), 1.50 (s, 9H).
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13

C NMR (75 MHz, CDCl3) [Figure

3.17] δ 170.2, 169.7, 168.3, 168.2, 168.1, 166.8 (6 C=O), 162.3, 158.2, 153.6, 151.2,
144.5, 142.4, 134.2, 128.3, 126.7, 124.2, 124.0, 112.0, 109.2, 100.1, 83.6 (C(CH3)3), 66.2
(OCH2-COO), 28.3 (3 CH3), 21.4(CH3CO), 21.0 (2CH3CO), 20.8 (CH3CO). MS
(C29H28O13), LRESI: [M+H+] 585.2, [M+Na+] 607.1, [M+K+] 623.1, [M+H+-CH2CO]
543.1. HRESI: [M+H+] 585.1606, Calculated 585.1603.

7-O-carboxymethyl quercetin tetraacetate 3

To 200 mg of 2 (0.38 mmol) in 4 mL anhydrous dichloromethane under nitrogen was
slowly added 1 mL dry trifluoro acetic acid. After 3 h stirring at room temperature the
solution was concentrated under rotatory evaporation under vacuum. The residue was
dissolved in chloroform, washed with water and then brine until the aqueous layer
becomes neutral. The organic phase was concentrated under rotavapor evaporation and
purified by flash column chromatography (ethyl acetate/hexane/acetic acid 4.5:4.5:1) to
afford 3 as a pale white solid in 72% yield (142 mg, 0.27 mmol). 1H NMR (500 Mhz,
(CD3)2CO) [Figure 3.18] δ 7.89 (dd, J=8.5, 2.0Hz, 1H), 7.85 (d, J=2.0Hz, 1H), 7.48 (d,
J=8.5Hz, 1H), 7.18 (d, J=2.0Hz, 1H), 6.85 (d, J=2.0Hz, 1H), 4.94 (s, 2H), 2.32-2.29 (m,
12H).

13

C NMR (151 MHz, (CD3)2CO) [Figure 3.19] δ 169.9, 169.0, 168.4, 168.1, 168.0,

168.0 (6 C=O), 163.1, 158.5, 153.6, 151.4, 145.3, 143.2, 134.3, 128.5, 126.9, 124.8,
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124.3, 111.7, 109.6, 100.5, 65.7 (OCH2-COO), 20.7, 20.2, 20.1, 20.0 (4 CH3CO). MS
(C25H20O13), LRESI: [M+Na+] 551.1, HRESI: [M+Na+] 551.0820 calculated 551.0802.

Quercetin-3, 5, 3’, 4’-tetraacetate 4

To quercetin penta-acetate (700 mg, 1.37mmol) in anhydrous dichloromethane at 0 oC
was added imidazole (93.2 mg, 1.37 mmol) and 181 mg thiophenol (1.2 equivalents).
After 1 h, at which point TLC indicated that the reaction was near completion, the
reaction was diluted with dichloromethane, concentrated under vacuum in a rotatory
evaporator, and the residue was dissolved in ethyl acetate. The organic phase was
washed with 1N HCl and then brine and concentrated to a residue. Flash column
chromatography (ethyl acetate/hexane: 4:3) afforded a yellow oil which was precipitated
with methanol to give 4 as a pale white solid in 65% yield (418 mg, 0.89 mmol)
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BioQ tetraacetate 5

Method I. Compound 3 (20 mg, 0.038 mmol) was first incubated with 1-ethyl-3-[3dimethylaminopropyl]carbodiimide hydrochloride (9.6 mg, 0.05 mmol) and Nhydroxysucciimide (5.7 mg, 0.05 mmol) in 50% MES buffer/acetonitrile (0.1 M, pH=5.5)
for 20 minutes. After addition of 6 (20 mg, 0.053 mmol) [26], the mixture was left
stirring under nitrogen atmosphere for 12 h at room temperature. The solution was then
vacuum concentrated to remove acetonitrile and the residue was added to 50 mL ethyl
acetate for extraction. The organic phase was washed with saturated ammonium chloride
and brine for three times each and then vacuum concentrated for purification by serial
column chromatography (5-8% methanol in dichloromethane) to finally afford 5 (5 mg,
0.006 mmol, 15%).
Method II. Compound 4 (20 mg, 0.042 mmol) and compound 7 (30 mg, 0.055
mmol) [26] were dissolved in 5mL anhydrous dimethyl formamide. The clear solution
was kept dry with 4 A0 molecular sieves under the protection of nitrogen atmosphere.
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Cesium carbonate (17 mg, 0.05 mmol) was then added at 0 C and the solution was left
stirring at room temperature for 1.5 hours during which the flask was wrapped with
aluminum foil to protect the reactants from light. Hydrochloric acid (1 M) was then
added to stop the reaction by making the solution weakly acidic (around pH 6). The
solvents are all vacuum concentrated and the remaining residue was purified by flash
column chromatography (5% methanol in dichloromethane) to afford compound 5 (33
mg, 0.037 mmol, 87%). 1H NMR (CDCl3 600 MHz ) [Figure 3.20] δ 7.73 (d, J=8.4Hz,
1H), 7.70 (s, 1H), 7.36 (d, J=8.4Hz, 1H), 7.07 (s, H-N in ethylene glycol, 1H), 6.91 (s,
1H), 6.72 (s, 1H), 6.45 (NH in biotin, 1H), 6.31 (NH in biotin, 1H), 4.64 (s, CH2, 2H),
4.51 (m, 1H), 4.32 (m, 1H), 3.60-3.37 (m, 12H), 3.15 (m, 1H), 2.88 (dd, 12.0 Hz, 4.2 Hz,
1H), 2.68 (d, 13.2 Hz, 1H), 2.43-2.34 (m, 12H, 4 CH3CO), 2.21 (m, 2H), 2.09 (acetic
acid), 1.67-1.62 (m, 4H), 1.43-1.41 (m, 2H).

13

C NMR (151 MHz [D6]DMSO) [Figure

3.21] δ 174.7, 173.6, 169.9, 169.7, 168.1, 167.9, 167.8, 167.2 (8 C=O), 164.5, 161.2,
157.9, 153.5, 151.0, 144.4, 142.3, 133.9, 127.8, 126.4, 124.0, 123.8, 112.0, 109.2, 100.0,
70.2, 70.1, 69.6, 69.5, 67.7, 62.0, 60.6, 55.0, 40.3, 39.2, 39.0, 35.6, 27.7, 25.2, 21.1, 20.7,
20.7, 20.6 (4 CH3). MS (C41H48O16N4S) LRESI: [M+H+] 885.3, [M+Na+] 907.3, [MCH2CO+H+] 843.3; HRESI: [M+H+] 885.2827, cal 885.2786, [M+Na+] 907.2618, cal
907.2686.
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BioQ 9.

A solution of compound 5 (30 mg, 0.034 mmol) in 10 mL tetrahydrofuran/phosphate
buffer/methanol (4.5:4.5:1, pH=7.4) was subjected to hydrolysis with N-methyl-2dimehtylamino-acetohydroxamic acid (4.5 equivalent, 20mg, 0.15mmol) under a nitrogen
atmosphere for 12 h. Hydrochloric acid (1 M) was added to work up the reaction by
acidifying the solution to pH 5. The mixture, after vacuum concentration, was extracted
with 50 mL ethyl acetate and washed with saturated ammonium chloride. The organic
phase residue was purified by high performance liquid chromatography (Solvent A:
water/1% acetic acid, Solvent B: acetonitrile/1% acetic acid; linear increase of solvent B
to 50% over 30 minutes and then to 100% over the following 10 minutes) to afford
compound 9 (18 mg, 0.025 mmol, 74%) at 32 min (retention time) (Figure 3.15). The
reactant (compound 5) was also analyzed by HPLC to have a retention time of 36.3min.
(Figure 3.14). Purity 98.27% (280nm). 1H NMR ([D6]DMSO, 300 MHz) [Figure 3.22] δ
8.20 (s, N-H), 7.82 (s, N-H), 7.72 (s, 1H), 7.56 (d, J=8.0Hz, 1H), 6.89 (d, J=8.0Hz, 1H),
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6.70 (s, 1H), 6.41 (s, 1H), 6.40 (NH in biotin, 1H), 6.36 (NH in biotin, 1H), 4.63 (s, CH2,
2H), 4.29 (m, 1H), 4.11 (m, 1H), 3.49-3.07 (m, 13H), 2.80 (dd, 12.0 Hz, 4.2 Hz, 1H),
2.58 (d, 13.8 Hz, 1H), 2.05 (m, 2H), 1.91 (s, acetic acid), 1.58-1.04 (m, 6H). 13C NMR
(151 MHz [D6]DMSO ) [Figure 3.23] δ 176.4, 172.5, 167.4, 163.5 (4 C=O), 163.1, 160.7,
156.2, 148.3, 147.8, 145.5, 136.5, 122.2, 120.4, 116.0, 115.6, 104.8, 98.4, 93.1, 69.9 (2 C
overlap), 69.6, 69.2, 67.6 (2 C overlap), 61.4, 59.6, 55.8, 38.8, 38.7, 35.5, 28.6, 28.4,
25.6. MS (C33H40O12N4S) LRESI: [M+H+] 717.2, [M+Na+] 739.3, [M+K+] 755.2.
HRESI: [M+H+] 717.2442, calculated 717.2363; [M+Na+] 739.2256, calculated
739.2263; [M+K+] 755.1984, calculated 755.3343.
Kinase inhibition and autophosphorylation assays. The kinase inhibition assay
and autophosphorylation assay were carried out with the PKLight assay kit for ATP
leftover by kinase (Lonza Rockland, Rockland ME), following the previously reported
procedure [21]. For the kinase inhibition test, casein kinase II (CK2) was incubated with
300 µM peptide substrate (RRRADDSDDDDD), 100 µM ATP in a buffer of 20 mM
Tris-HCl, 50mM KCl, 10mM MgCl2 at 30oC for 30 min, with inhibitors added in
increasing concentrations; preactivated Ca2+/ calmodulin-dependent protein kinase II
(CAMK2) was mixed with increasing concentrations of inhibitor, 300 µM autocamtide-2
(KKALRRQETVDAL), 100 µM ATP in a pH 7.5 buffer of 50 mM Tris-HCl, 10 mM
MgCl2, 2 mM DTT, 0.1 mM Na2EDTA at 30oC for 30 min. Autophosphorylation assay
for CK2 (0.035, 0.07 and 0.35 µM) was carried out in presence of 1 µM ATP, 10 µM
quercetin in a buffer of 20 mM Tris-HCl, 50 mM KCl, 10 mM MgCl2 at 30 oC for both
10 min and 40 min, with or without 300 µM peptide substrate (RRRADDSDDDDD).

110

Model peptide photocrosslinking study. 100 µM Angiotensin I peptide
(NRVYIHPFHL) and 100 µM Substance P (RPKPQFFGLM) were mixed with 4 mM
BioQ in 200 µL of 10 mM PBS buffer, pH 7.2, and irradiated under the photoirradiation
conditions described for the protein pull down assays. After irradiation the sample was
diluted 50-100 fold and subjected to LC-MS/MS analysis [Figure 3.9].
Western blotting of HSP70 and biotin labeled proteins. Western blotting to detect
heat shock protein 70 generally followed a previously described procedure [21]. For the
detection of biotin, proteins were transferred from the SDS polyacrylamide gels to nitrocellulose membranes which were then immersed in 3% BSA overnight at 4 °C to block
non-specific binding. After washing with PBS Tween buffer, the blots were incubated
with horseradish peroxidase (HRP) conjugated anti-biotin antibody for one hour. The
blots were finally stained in a 50 mL solution containing 30 mg 4-chloro-1-napthol and
0.01% hydrogen peroxide which produces a purple color at sites of horseradish
peroxidase (HRP) activity.
General procedure for protein pull down experiments. The protein solution, cell
lysate or cell suspension was irradiated for 30 min in a glass tube that was immersed in
ice 10 cm away from a 450 W UV medium pressure mercury arc lamp in a water cooled
immersion apparatus that was shielded with Wood’s glass (transmits ultraviolet between
320 and 400 nm with a peak at 365 nm). The cell suspension was then lysed as described
in a subsequent section, and the protein-containing solutions and cell lysates (400 L - 1
mL) were incubated with 20 L of streptavidin agarose beads for 1 h. The binding of
BioQ to beads was monitored by a color change from white to yellow, due to the
presence of quercetin. The beads were then centrifuged at 14000 rpm for 5 minutes and
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the supernatant removed. The beads were then washed by treatment with lysis buffer (10
mM phosphate buffer, pH 7.2, 100 mM NaCl, 0.2% Triton X-100, and protease cocktail)
or denaturing buffer (20 mM Tris•HCl, 2% SDS, pH 7.4) and shaken well for three
minutes before each spin-down collection. The washing procedure was repeated at least
three times. The beads were then resuspended in 20 l of 2  SDS-PAGE gel loading
buffer (50 mM TrisHCl, 100 mM dithiothreitol, 8 M urea, 2% SDS, 10% glycerol) and
boiled for ten minutes in order to denature the streptavidin and release the biotin
conjugates. Samples were loaded to SDS polyacrylamide gel and ran under 125 V for
around one hour at which point the 10 kD protein would reach the bottom of the gel. The
gel was then silver stained.
BioQ pull down of casein kinase II in vitro. The indicated concentrations of casein
kinase II were mixed with 150 M BioQ in 0.01M PBS buffer/protease cocktail (pH 7.2),
or 0.01 M PBS buffer (pH 7.2)/protease cocktail/2 M ATP/Mg2+. Photocrosslinking
was carried out with 400 L of solution for 30 minutes and then immediately incubated
with the streptavidin beads and processed as described above.
BioQ protein pull down from Jurkat cells. Jurkat cells were exponentially grown
in RPMI media with 10% fetal bovine serum, until about 15×106 cells were obtained,
after which the cells were harvested and treated with 3% aqueous DMSO as blank
controls or 150 M BioQ in 3% aqueous DMSO for two hours prior to a 43 C heat
shock, then allowed to recover at 37 C for 1 h when the level of active heat shock factor
in the cells typically reaches a maximum. The Jurkat cells were then cooled to 0 oC while
being transported to the UV facility (10 min), where they were UV-irradiated as
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described above at 4 C immediately before or after cell lysis. The Jurkat cells were
lysed by sonication in a cold room in 2 mL of cell lysis buffer (10 mM phosphate buffer,
pH 7.2, 100 mM NaCl, 0.2% Triton X-100, and protease inhibitors) and centrifuged at
5000 rpm for 10 min. The supernatant was then incubated with the streptavidin beads
and processed as described in the general procedure.
Silver staining of SDS-PAGE gel. The SDS polyacrylamide gels were incubated
overnight in 100 mL solution of ethanol: glacial acetic acid: water (30:10:60) with gentle
shaking to fix proteins. After washing with deionized water, the gel was silver stained
either by a published procedure [24], or using the Pierce Silver Stain Kit (Pierce).
In-gel trypsin digestion. All equipment was first thoroughly washed with 70%
ethanol followed by deionized water using non-latex gloves and a face mask. Silver
stained bands were immediately excised with a gel cutter or scalpel blade, taking only the
stained gel area. The excised bands as well as corresponding sections from a control lane
were further cut into small pieces and collected in microfuge tubes, into which destaining
buffers supplied with the silver SNAP stain kit were added. After destaining, gel pieces
were washed at least three times with 100 mM sodium bicarbonate until the gel color
turned a pale white. Acetonitrile (200 l) was added to each tube for 5 min to dehydrate
the slices, and then removed, after which the samples were dried by centrifugal
evaporation in a Speedvac. Oxidized cysteines were reduced by adding 50 L of 10 mM
DTT/50 mM ammonium bicarbonate to the dried slices for 30 min at room temperature.
After decanting the DTT solution from the gel slices, they were incubated with 50 mM
iodoacetamide solution in 50 mM ammonium bicarbonate for 30 min at room
temperature in the dark to cap the freshly reduced cysteines. The gel slices were then
113

washed three times with 100 mM ammonium bicarbonate and two times with 50 mM
ammonium bicarbonate in 50% acetonitrile. The gel slices were dehydrated with 200 L
of acetonitrile for 5 min and then 500 L acetonitrile for 20 min. After removal of the
acetonitrile, the samples were completely dried in a centrifugal evaporator and subjected
to trypsin digestion. Promega sequencing grade trypsin (10 ng) was dissolved in 1 mL
ice-cold 50 mM ammonium bicarbonate and 20-50 L was added to each sample on ice
and incubated in a cold room for 1 h at which point the gel pieces had completely
rehydrated and swelled. Excess trypsin solution was then removed and enough 50 mM
ammonium bicarbonate was added to cover the gel pieces to keep them hydrated while
digested overnight. After 12 h, the liquid was transferred to microfuge tubes on ice and
the gel pieces were then extracted with 1% trifluoroacetic acid / 50% acetonitrile in water
for 10 min with sonication and combined with the previous extract. The extraction was
repeated again with 10% trifluoroacetic acid / 50% aqueous acetonitrile. The combined
extracts were lyophilized in SpeedVac and resuspended in 0.1% TFA, followed by C-18
zip-tip (Millipore) desalting to provide clean peptide fragments for liquid
chromatography / mass spectrometric analysis.
LC MS/MS of trypsinized proteins. A 75 um i.d. fused-silica capillary column was
packed with C18 reverse-phase material (Magic, 5um, 300 A, Michrom, CA) and preequilibrated with 100% solvent A (water, 0.1% formic acid). For each single run, 5 µL of
digested sample was loaded to the column and subjected to gradient elution from 2%
solvent B (3% water, 97% acetonitrile, 0.1% formic acid) to 50% solvent B over 50 min,
followed by an increase to 85% solvent B in 5 min at a flow rate of 260 nanoliter /min,
followed by a 5 min re-equilibration. The solution out of the column was directly
114

sprayed into an LTQ-Orbitrap mass spectrometer (Thermo Fisher, Waltham, MA), using
a PicoView PV-500 nanospray source (New Objective,Woburn, MA). A full mass
spectrum of eluting peptides was obtained with the FT mass spectrometer component at
high mass resolving power (100,000 for ions of m/z 400). Ions submitted to MS/MS
were placed in a dynamic exclusion list for 8 seconds. The MS/MS collections for the six
most abundant eluting ions were performed with wide-band activation, in the LTQ mass
spectrometer at normalized collision energy of 35%, with a 2 Da isolation width. Raw
data was uploaded to Mascot licensed version (Matrix Science, MA) and submitted to
identity search through NCBInr database. MS/MS results on the model peptide were
manually analyzed with Xcalibur software (Thermo scientific, USA).
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Table 1. IC50 values for casein kinase II (CK2) and calmodulin-dependent kinase II
(CAMK2) inhibition using the PKLight protein kinase assay.
Quercetin (M)

BioQ (M) (IC50)

CK2

5.6 ± 1.2

3.2 ± 0.7

CAMK2

3.0 ± 0.6

25.9 ±0.8
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Table 2. LC-MS/MS identification of proteins pulled down from Jurkat cells using
Mascot.1
Band App. Name

Gene
ID

MW
A

110 ubiquitin-activating enzyme E1
(UBA1)
spliceosomal protein SAP 130
(SF3B3)

GI number

MW

Mascot
score

7317

23510338

118,858

205

23450

6006515

136,590

252

B

100 heat shock protein HSP 90-alpha
2 (HSP90AA1)

3320

61656603

98,622

663

C

70 heat shock protein 70-2 (HSPA2)

3306

23271312

70,237

524

D

50 RuvB-like 2 helicase ATPase
(RUVBL2)

10856

5730023

51,026

450

506

32189394

56,525

447

8665

4503519

37,654

179

mitochondrial ATP synthase beta
subunit ATPase (ATP5B)
E

40 eukaryotic translation initiation
factor 3, subunit 5 epsilon
(EIF3F)

F

37 unknown

1

The target proteins were identified by comparison of the proteins detected in a control

and sample band so that contaminating keratins and albumins were excluded.
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Figure 3.4 COSY spectrum of BioQ. Numbers correspond to the proton assignments, and the
letters correspond to the 1H-1H correlations shown in Figure 3.3.
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Figure 3.5 HMQC spectrum of BioQ. Numbers correspond to the carbon assignments for the
one bond 13C-1H correlations shown in Fig. 3.3.
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letters correspond to the 13C-1H correlations shown in Figure 3.3.
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Figure 3.7 Ability of BioQ to inhibit heat shock induction of HSP70 in Jurkat cells. Jurkat cells
were treated with quercetin (Q), DMSO vehicle (V) or BioQ (BQ) for 2 h prior to a 30 min 43°C
heat shock (HS) then allowed to recover at 37C for 8 h before Western blot analysis of HSP70
and actin levels. Control unheated Jurkat cells (C) and heated Jurkat cells in the absence of any
additive (-). Both quercetin and biotinylated quercetin were utilized at 145 µM. The results were
repeatable.
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Figure 3.8 Photobleaching of Quercetin and BioQ. The ultraviolet-vis spectrum of quercetin
and biotinylated quercetin in 10 mM pH 7.2 PBS buffer, before and after irradiation for 10 min
intervals (top to bottom) with Woods glass filtered medium pressure mercury arc light.
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Figure 3.9 LC MS of irradiated DRVYIHPFHL and BioQ. A) top panel: LC ion trace for mass
432.89 corresponding to peptide +3H+. Bottom panel: LC ion trace for mass 627.64
corresponding to peptide + BioQ fragment + 3H+. The tail on the peak for the 432.89 triply
charged peptide ion is due to decomposition of the adducted peptide in the ESI source.
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B)

Figure 3.9 LC MS of irradiated DRVYIHPFHL and BioQ. B) Top panel: MS/MS of [M+H]+ =
585.22 corresponding to the photoproduct of BioQ with key fragmentations identified. Bottom
panel: MS/MS of [M+3H]3+ = 627.67 corresponding to the peptide adduct of Figure 3.9A bottom
panel, showing presence of the same BioQ fragment.
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Figure 3.10 Casein Kinase II pull down by BioQ. Increasing concentrations of CK2 (lanes 3-6:
17.5, 35, 52.5, 70 nM) in 400 L, 10 mM PBS buffer (pH 7.2), were incubated with 150 M
BioQ and then photoirradiated at 365 nM for 30 min in the (a) absence or (b) presence of 10 mM
MgCl2 and 2 M ATP. The biotinylated proteins were then pulled down by streptavidin beads
and subjected to a denaturing wash prior to electrophoresis. L is a Fermentas prestained protein
ladder. Lanes a1 and b2 contained 0.05 µg CK2, and lanes a2 and b1 contained 0.1 µg of CK2.
The positions of the α and β subunits of CK2 are identified on the gel, as well as the contaminant
keratin.
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Figure 3.11 Autophosphorylation of CK2. Luciferase coupled assay for ATP consumption of
CK2 incubated with quercetin in the presence and absence of the peptide substrate
(RRRADDSDDDDD).
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Figure 3.12 Proteins pulled down from Jurkat cells incubated with BioQ that were UV irradiated
following lysis. Left: Silver stained 12% SDS polyacrylamide electrophoresis gel of proteins.
Lanes 1 and 2: proteins pulled down from lysates of normal or heat shocked Jurkat cells in the
absence of BioQ and UV irradiation. Lanes 3 and 4: proteins pulled down from lysates of normal
or heat shocked cells that had been incubated with 150 M BioQ in absence of UV irradiation.
Lanes 5 and 6: proteins pulled down from lysates of normal or heat shocked cells that had been
incubated with BioQ and UV irradiated following lysis, and then subjected to a denaturing wash.
Lane 7: proteins pulled down under the same conditions as for lane 6, except that the lysate was
not UV irradiated. Right: Western blot of corresponding lanes with anti-biotin antibody.
Legend: heat, heat shock applied after incubation with BioQ but before lysis; wash, washing
beads with cell lysis buffer; denaturing wash, washing beads with 2% SDS buffer.

135

L

1

BioQ
Heat
UV
+
Wash
Denat. wash

2

3
+

+
+

+
+

4
+
+
+
+

5
+

6
+
+

7
+
+

8
+
+
+

+

+

9
+

+
+

+

10
+
+

11
+

+

+
+

12
+
+
+
+

13

14

+
+

+
+
+

130
100
70
55

A/B
C
D
E

40

F
35
25

kD

Figure 3.13 Proteins pulled down from Jurkat cells irradiated with BioQ prior to lysis. Left:
Proteins pulled down with streptavidin beads from Jurkat cells under similar sets conditions as in
the gel in Figure 3.12. Right: Western blot with anti-biotin antibody.
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Figure 3.14 HPLC spectrum of compound 5.
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Figure 3.15 HPLC spectrum of compound 9.
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HNMR (300MHz, CDCl3) spectrum of compound 2.
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CNMR (75MHz, CDCl3) spectrum of compound 2.
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HNMR (500MHz, [D6] (CD3)2CO) spectrum of compound 3.
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CNMR (151MHz, [D6] (CD3)2CO) spectrum of compound 3.
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Figure 3.20
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HNMR (600MHz, CDCl3) spectrum of compound 5.
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Figure 3.21
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CNMR (151MHz, [D6]DMSO) spectrum of compound 5.
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Figure 3. 22
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HNMR (300MHz, [D6]DMSO) spectrum of compound 9.
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Figure 3. 23

13

C NMR (151MHz, [D6]DMSO) spectrum of compound 9.
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Chapter 4.
Inhibition of Heat Shock Transcription Factor Binding and
Heat Shock Protein 70 Induction in vivo by a Linear
Polyamide Binding in a 1:1 C→N Mode

The text of this chapter was taken in part from a manuscript coauthored with Raj K.
Pandita, Jianfeng Cai, Clayton R. Hunt and John-Stephen Taylor (Washington
University)
(Rongsheng E. Wang, Raj K. Pandita, Jianfeng Cai, Clayton R. Hunt & John-Stephen
Taylor, 2010, Manuscript submitted)
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Abstract
Heat shock proteins (HSPs) are known to protect cells from heat, oxidative stress, and the
cytotoxic effects of drugs, and thus can enhance cancer cell survival. As a result, HSPs
are a newly emerging class of protein targets for chemotherapy. Among the various
HSPs, the HSP70 family is the most highly conserved and prevalent. Though a number
of small molecule inhibitors of HSP70 induction are known, they have a number of
drawbacks with regards to toxicity, potency, and specificity. Herein I am describing the
development of a β-alanine rich linear polyamide that binds the GGA heat shock
elements (HSEs) 3 and 4 in the HSP70 promoter in a 1:1 mode and inhibits heat shock
transcription factor 1 (HSF1) binding in vitro and HSP70 induction in vivo.
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Introduction
Although heat shock protein 70 (HSP70) is recognized as an emerging protein target for
chemotherapy, few inhibitors have been developed so far that have potential to be
administrated as drugs, due to the obstacle in druggability of HSP70, as explained in
chapter 1. Of the known small molecule inhibitors of HSP70 induction, such as
triptolide, KNK 437 and quercetin, quercetin requires high concentrations and, though it
is known not to be toxic in humans, lacks specificity, inhibiting many off-target kinases
and enzymes [1, 2]. However, quercetin appears to have an easy-modifiable structure
and interfere with HSF1 activation by inhibiting HSF1phosphorylation to block the
HSP70 induction [3] , making its derivative have advantage in potential specificity over
other inhibitors which interfered with the down-stream pathways of HSP70 expression.
We therefore introduced the optimization and study of quercetin derivatives and the
identification of possible targets in previous chapters.
Besides the development of small molecules, a more general approach to
developing HSP70 inhibitors as chemotherapeutic drugs would be to make use of highly
programmable gene-specific agents, such as antisense, siRNA, and antigene agents,
whose pharmaceutical properties might be more predictable and readily tailored [4].
Among these potential agents, nucleic acid-based agents such as antisense
phosphorothioates, locked nucleic acids, siRNAs, and peptide nucleic acids can be made
to predictably bind to their nucleic acid targets by simple Watson Crick base pairing [4,
5]. Unfortunately, all of these nucleic acid-based agents have poor membrane
permeability, necessitating the use of liposomal, cell penetrating peptide, or nanoparticle
delivery systems [4]. Anti-gene agents based on polyamides can also recognize a target
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DNA sequence through predictable H-bonding interactions with the minor groove, but
unlike antisense agents, have better membrane permeability properties [6, 7]. Minor
groove binding polyamides have been shown to inhibit transcription factor binding in the
minor groove through allosteric effects and by modifications that interfere with phosphate
contacts [8-10]. Polyamides are also attractive for drug development, because they can
be conveniently synthesized by standard Fmoc or Boc solid phase peptide synthesis
methods.
Polyamides consist of oligomers of N-methyl-imidazole (Im) and N-methylpyrrole (Py) linked together through amide bonds [11]. Watson-Crick base pairs are
recognized by hydrogen bonding in the minor groove with Im/Py recognizing G/C, Py/Im
recognizing C/G, and Py/Py recognizing either A/T or T/A (Figure 4.1). N-methyl-3hydroxypyrrole (Hp) can be used to discriminate between A/T from T/A base pairs by
preferentially recognizing thymidine. Up to seven Im and Py units have been linked
together to form linear polyamides with binding affinities in the nM concentration range
[12]. The binding affinity drops after more than seven units because of divergent
curvature of the polyamide and the minor groove. The binding size limit can be
overcome by introduction of a flexible β-alanine linker, which makes it possible to create
linear polyamides of 16 units in length, to target AT rich nucleic acid [13].
X-ray crystallography has revealed two binding modes, a 2:1 mode in which two
polyamides bind in an antiparallel fashion to the DNA in either a fully overlapped or
slipped form [12], and a 1:1 mode in which one polyamide binds in a single orientation
[14]. While for most sequence contexts, polyamides bind in a 2:1 mode, polypurine
sequences are bound in a 1:1 mode, which is proposed to result from a narrower minor
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groove that prevents binding of second polyamide [15, 16]. It has also been observed that
in polypurine rich sequences, linear polyamides tend to bind in the opposite direction
(C→N, 5’→3’) compared to most sequences (N→C, 5’→3’) [14, 15].
Transcriptional induction of HSP70 involves trimerization and binding of the heat
shock transcription factor (HSF1) to the major groove of the heat shock elements (HSEs)
which consist of 3-4 tandem inverted repeats of a core NGAAN DNA element. Though
polyamides bind to the minor groove, there are numerous examples in which hairpin
polyamides can be made to inhibit major groove binding by incorporation of conjugated
amino acids that block protein contacts with the major groove and/or DNA backbone
[17], or by altering the geometry of the major groove [10, 18-20]. With regards to
binding the heat shock element NGAAN motif, a linear polyamide has been previously
designed to bind in a 1:1 mode to long GAA•TTC repeats in Friedreich’s ataxia [16].
Herein, I report on the synthesis and binding properties of a series of linear polyamides
targeted to the human heat shock elements, and demonstrate for the first time, inhibition
of transcription factor binding by a polyamide binding in a 1:1 linear binding mode.

Results
There are three heat inducible HSP70 genes in humans, of which HSPA1A and HSPA1B
are the most conserved and bear the same promoter structure [27]. Promoters of heat
inducible HSP70 genes contain multiple adjacent and inverted NGGAN motifs, or heat
shock elements (HSEs) that are recognized by the heat shock transcription factor, HSF-1.
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Five adjacent HSEs are found in the HSPA1A/HSPA1B genes, two of which (site 3 and
4) (Figure 4.2a) are part of a sequence with dyad symmetry (GGAATATTCC). HSF-1
binds the heat shock promoter as a trimer and both footprinting and single nucleotide
deletion analysis have shown that it preferentially binds to sites 3 and 4. The five HSEs
manifest a distorted structure, especially after site 1 and 3, as evidenced by
methidiumpropyl-EDTA footprinting [28]. It was proposed that purine tracts at site 1 and
3 have twisted DNA strands and narrowed minor grooves, which help the heat shock
transcription factor contact the major groove.
Hairpin polyamide design and synthesis. The critical heat shock elements HSE3
and HSE4 within the HSP70 DNA promoter are quite challenging to target with
polyamides because there is evidence from MPE footprinting that the DNA minor groove
is distorted and much narrower than at polypurine tracts [28]. Recognizing that HSE3
and HSE4 were part of a pallindromic site, we initially decided to target the GGAAT
sequence with a hairpin polyamide, as a hairpin polyamide has been previously
successfully used to target the related sequence, GGAAA contained in the NF-kB binding
site [9]. To this end I synthesized hairpin polyamides H0-H3 (Figure 4.2b). H1 was
composed of only imidazole and pyrrole amino acids, whereas for H2 and H3 I replaced
one pair of the pyrrole amino acids with β-alanine to relieve any potential strain induced
by the site. β-alanine is preferred relative to pyrrole in structurally rigid DNA sites
because of its flexibility [15]. H0 was used as a mismatch control for H1. The hairpins
were synthesized by conventional solid phase Fmoc-synthesis on an oxime resin [22], in
yields of 10%-20%.
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Binding Sites and Affinity of the Hairpin Polyamides. Binding of the hairpin
polyamides was determined by quantitative DNase I footprinting [26]. 5’ Radiolabelled
152-mer DNA prepared by PCR containing the heat shock promoter was incubated with
various concentrations of polyamide and subjected to DNase I cleavage. The extent of
inhibition of DNase I cleavage at the observed binding sites as a function of polyamide
concentration was then fit to a Hill-slope equation. DNase I footprinting showed that
only H1bound specifically to the DNA at concentrations below 1 µM and at two distinct
sites (Figure 4.3). One footprint not only encompassed the HSE3 and HSE4, but also
HSE1 and 2, which contain a GGTTT site that could also be bound by H1. The site
higher up on the gel (E) corresponds to a site that also contained a GGAA site.
Quantitative footprinting over the range of 100 to 500 nM gave the best fit for a fixed
Hillslope of 1 with a binding constant of only 3.0 ± 0.4  105 M-1 for the HSE1-4 sites.
The observed binding affinity is a much lower than that of 1.3 ± 0.2 × 109 M-1 that was
reported for the corresponding GGAA site in the NF-B site [9]. Because this polyamide
had such a low binding affinity and did not show any inhibition of HSF1 binding to the
HSE (data not shown), we decided to investigate linear binding modes.
Linear Polyamide Design and Synthesis. It has also been shown that a GGAA
sequence can be bound by linear polyamides in a 2:1 mode, N-C, 5’-3’ orientaion at a
quasi pallindromic site (AGGGAATCCCCT) [29]. A β-alanine was used to link two
four-ring-polyamides to enable recognition of the longer site. We therefore designed a
similar set of polyamides, in which additional pyrroles were also substituted with βalanines in anticipation of stress induced by the HSE sequence. The number of βalanines that can be used is limited, however, by the observation that too many β-alanines
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decrease nuclear localization and cell permeability [16, 30]. We therefore designed a
library of polyamides bearing a β-alanine opposite different A’s and T’s along with βalanine at the carboxy terminus that originates from using a β-alanine solid phase support.
This library consisted of four polyamides (P1, P2, P3, and P6) bearing two β-alanines,
and one polyamide (P10) bearing a single β-alanine at the C-terminus to serve as a
control (Figure 4.2c). Because we wanted to avoid having two β-alanines adjacent to
each other at the C-terminal end, the polyamide in which the Py of P10 opposite T3 that
would have been replaced with β-alanine was not synthesized. Polyamides containing an
additional β-alanine were also synthesized (P5 and P9), in which no two β-alanines were
adjacent to each other.
The first library of linear polyamides was designed to bind in the conventional
N→C vs 5’→3’ direction [7]. Due to the dyad symmetry of the DNA sequence being
targeted, polyamides P1, P2, P3, P5, P6, P9 and P10 were expected to bind to either
strand in a linear 1:1 mode, or simultaneously in a 2:1 mode. A second library consisting
of P7, P4, and P8 was designed to bind in the C→N direction that has been observed to
be preferred for polypurine sequences [14, 15]. The polyamide was also shifted to
recognize the T to the 5’-side of the pallindromic sequence on the top strand (T-6) in an
effort to enforce a unique orientation that might be detectable by footprinting. The
bottom strand has a G at this position (Figure 4.2c). The sequences of the second library
were based on the P5 sequence, after it was found to have the highest affinity in
footprinting assay (Figure 4.4) among the members of the first library (vide infra). P11
and P12 were double mismatch controls for the first and second libraries, respectively.
The polyamides were synthesized by solid phase Fmoc synthesis [21] and had yields
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around 40% for P10, but lower yields when more β alanine building blocks were
included. P1, P2, P3, P6 and P7 were obtained in yields between 20% and 30%, while
P5, P9, P4, P8, P11 and P12 were obtained in yields between 10% and 20%.
Binding Sites and Affinity of the Linear Polyamides. The binding sites and
affinity of the linear polyamides were also determined by quantitative DNase I
footprinting as was carried out for the hairpin polyamides. Polyamides P1, P2, P3, P6
and P10 having one or no β-alanines in the body portion were the weakest binders as they
did not show any readily discernable footprint at concentrations up to 500 nM (Figure
4.4a). Polyamides consisting of two β-alanines (P5 and P9) in the body portion showed a
detectable footprint at the HSE3/4 site at 100 nM polyamide (Figure 4.4b). The
mismatch polyamide P11, in which Im and β were switched, showed no distinct
inhibition until 500 nM, at which point binding was fairly non specific (Figure 4.4c).
Association constants determined by quantitative analysis of the footprinting gels (Table
4.3), show that within the limits of error, that the 8-mer polyamides binding in the N→C
direction relative to the 5'→3' DNA direction (P5 and P9) have Ka's of approximately 1 
107 M-1. Whereas P9 appeared to bind in a 2:1 mode (Hillslope coefficient of 1.5), P5
appeared to bind in a 1:1 mode (Hillslope coefficient of 0.9).
Significantly higher binding affinity was observed for the second library of
polyamides, P7, P4 and P8, which were designed to bind in the opposite direction (C→N)
and asymmetrically to the two nucleotides to the 5'-side of HSE3 as shown in Figure 4.5.
Whereas a footprint only began to emerge at about 100 nM for P7, much like for P5 and
P9, a footprint began to emerge at 0.1 pM for the longer polyamides, P4 and P8.
Quantitative analysis of the footprints in a lower concentration range (Figure 4.7) show
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that polyamides P7, P4 and P8 have much higher affinity per amino acid than those
binding in the normal direction, with Ka's of 1.15  107 M-1 for the 6-mer P7 to 3.44×108
M-1 for the 9-mer (Figure 4.8, Table 4.3). Within this group of polyamides, the binding
affinity can also be seen to increase with increasing length, in the order P7 < P4 < P8.
Binding to n+1 on-targeted sites was observed to occur at the 3'-end of the promoter
sequence for P4 and P8, but only at 100 nM and higher concentrations. The mismatch
control for P8, polyamide P12, only bound to DNA substrate non-specifically at
concentrations of 400 nM and above (Figure 4.5). All of the C→N binding polyamides
appeared to bind in a 1:1 mode based on the Hill Slope coefficient (Figure 4.8, Table
4.3).
Although DNase I footprinting is not able to determine the exact bases bound by a
polyamide, or the orientation of the polyamide, close examination of the footprints for
P7, P4 and P8 reveals an increase in the protected site with an increase in the size of the
polyamide (Figure 4.6). Comparison of the blocked sites in the bracketed section of the
gel indicates that the relative intensity of one cleavage band is greatly diminished in
going from P7 to P4, and that then next band is lost in going from P7 to P8. Thus,
increasing the polyamide chain length at the N-terminus increased its DNA binding and
hindered DNase I accessibility to the bound DNA. The loss of DNase I bands on going
from P7 to P4 to P8 is most consistent with the C→N orientation along the 5’→3’
direction on the top strand, though we cannot rule out the same binding to the bottom
strand in the reverse orientation.
In vitro inhibition of HSF-1 binding to heat shock element DNA by polyamides.
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The ability of the polyamides to block binding of HSF-1 to its cognate heat shock
element (HSE) DNA promoter sequence was determined by a gel mobility shift assay.
Radiolabeled HSE oligodeoxynucleotide duplex (10 nM) was incubated with different
polyamides at 100 nM before mixing with nuclear extracts prepared from heated Jurkat
cells and the formation of HSE/HSF-1 complexes determined by gel electrophoresis
(Figure 4.9). As expected, the HSE/HSF-1 complex readily forms with extracts prepared
from heated control cell nuclei (lane C, position of arrow) in the absence of added
polyamide. Addition of polyamides P1-P7, P9-P10 or P11-P12 to the HSE binding
reactions did not significantly decrease complex formation. Polyamide P10 appeared to
cause aggregation as a significant amount of material was trapped in the gel well.
Polyamide P8, however, decreased the level of HSE/HSF-1 complex formed to 35% of
control, indicating that polyamide binding either altered the DNA structure or was
otherwise inhibiting HSF-1 access to the DNA structures required for complex formation.
We then incubated the DNA with different concentrations of polyamides P8, P11 and
P12, to determine the minimum inhibitory concentration (Figure 4.10). Whereas P11 had
no effect on complex formation over a range of 10 to 100 nM, the P8 polyamide inhibited
complex formation at 50 and 100 nM but not at lower concentrations (Figure 4.10a).
Similar observations were made for P8 versus P12 (Figure 4.10b).
Polyamide inhibition of HSP70 expression in vivo. The ability of P8 and the P11
control polyamides to inhibit HSP70 expression in vivo was determined by measuring the
level of HSP70 protein in Jurkat cells after heat shock. Jurkat cells were chosen because
they have a very low basal level of HSP70 which is highly induced by heat [31]. Because
no effect on HSP70 induction was observed on cells passively treated with the
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polyamides, cells were electroporated with 5 M P8 or P11 and then allowed to recover
for 24 h in the presence of 5 M polyamide before being heat shocked at 43 C for 30
min to induce HSP70 gene transcription and protein synthesis. Western blot analysis of
HSP70 protein levels (Figure 4.11), normalized to actin protein levels and corrected for
cell viability, indicated that the P11 control polyamide had no effect on HSP70
expression (102 ± 6 % of control) while P8 decreased HSP70 levels to about 60% of
normal (58 ± 9 %). This result is consistent with the gel shift analysis, which showed that
polyamide P8 and not P11 inhibits HSF-1 binding to the heat shock promoter DNA
elements required for transcriptional activation of HSP70 expression. The actual amount
of HSP70 suppression may be greater than 40% if the HSP70 antibody is cross reacting
with untargeted B’ (also known as HSP70-6, HSPA6), which is also heat inducible, in
addition to polyamide targeted HSPA1A/HSPA1B [32].

Discussion
There are several examples hairpin or cyclic polyamides that inhibit transcription
factor binding to the DNA major groove, presumably by altering the minor groove
conformation and as a consequence the major groove conformation [10, 18, 19, 33].
There are also some examples of linear polyamides that can alleviate inhibition of
transcription in expanded GAATTC repeats that appear to work by stabilizing a B DNA
conformation and interfering with intramolecular triplex formation and intermolecular
interactions [16]. There have not to our knowledge been any reports of linear polyamides
that can inhibit transcription factor binding.
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The human HSP70 heat shock promoter is composed of five heat shock elements
[28], three of which are GAATTC sequences, and two of which, HSE3 and HSE4, are
involved in an inverted repeat separated by a TA sequence that would allow binding by
both 1:1 and 2:1 modes. The heat shock elements are extremely twisted, suggesting that
transcription factor binding might be inhibited by a polyamide that would stabilize a less
twisted DNA conformation. Polyamides have usually been observed to bind from the N
to C direction relative to the 5' to 3' direction of the DNA sequence, the only exception
occurring with purine rich DNA sites, where an opposite orientation is observed [15].
Because the heat shock promoter contains both purine rich and mixed sequences, we
designed hairpin and linear polyamides with both N to C and C to N orientations targeted
to HSE3/4.
Our initial attempts with designing a hairpin polyamide to bind to the GGAA
sequence along previously successful lines for a similar site in the NF-B site [9], only
yielded a weak binding polyamide that was not able to inhibit heat shock transcription
factor binding in vitro. It may be that the conformation of the HSE3/HSE4 DNA does
not support the hairpin motif. It was for this reason that we turned our attention to linear
polyamides.
Because polyamide P10, which was composed of only internal pyrrole and
imidazole building blocks, failed to bind to the HSE effectively, selected pyrroles were
replaced with the more flexible β-alanine unit to improve polyamide curvature [15].
Different polyamide libraries incorporating an increasing number of internal β-alanines
were prepared, of which only polyamides containing two internal β-alanines, P5 and P9,
manifested binding to heat shock DNA elements at concentrations above 100 nM. The
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region of protected DNA corresponded to the targeted 5’-GGAATTCCC-3’ sequence of
HSE3 and HSE4. Due to the pallindromic nature of this sequence P5 and P9 could be
binding to either strand, or both, in an N→C orientation.
Because HSE3/4 contains polypurine tracts, it was also possible that the polyamides
could bind in the C→N [14, 15]. In support of this idea, polyamide P8, which was
designed to bind to the top strand with the C→N orientation by recognizing the T to the
5’-side of the pallindromic sequence, had significantly higher binding affinity than the
sequences designed to bind in the N→C orientation. Also consistent with this analysis
was the increase in the DNase I footprint size on going from P7 to P4 to P8 towards the
3'-side of the HSE3/4 sequence expected if the polyamides were binding to the top strand
(Figure 4.6). In the case of the heat shock elements, the presence of two opposing
polypurine tracts disrupted by a TA sequence may allow binding of polyamides in both
N→C and C→N orientations. It is also noteworthy that linear polyamides generally
adopt a 2:1 binding mode in the minor groove of mixed sequences, whereas all the
polyamides investigated herein appear to bind in a 1:1 mode, with the possible exception
of P9 (Table 4.3). It may be that pre-twisted nature of the sequence containing two HSE
elements with dyad symmetry precludes binding of a second polyamide, whereas shorter
sequences targeting only one HSE may be able to bind in a 2:1 cooperative mode.
Given the high association constant of P8, an in vitro gel shift assay was carried out
to determine whether P8 specifically blocked heat shock factor binding to heat shock
element (HSE) DNA. At a concentration of 100 nM, P8 effectively inhibited HSF
binding while both P11 and P12, which had sequence mismatches, showed no activity
(Figure 4.10). This result was consistent with a screen of all the linear polyamides at 100
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nM that identified P8 as the most effective inhibitor (Fig. 4.9). Initial attempts to inhibit
HSP70 induction in vivo by addition of P8 to the culture medium failed, suggesting that
the polyamide might not be entering the cells efficiently as has been previously observed
for longer polyamides [16]. When the P8 polyamide was electroporated into cells, an
approximately 40% decrease in heat induced HSP70 protein synthesis was observed
(Figure 4.11) indicating the ability of P8 to inhibit HSP70 induction in vivo. It may be
that incorporation of the β-alanines hampers cell permeation by polyamides, [30, 34] and
that future studies will need to focus on improving cell delivery [35, 36]. The 40%
inhibition of HSP70 induction is promising, though effective suppression of the heat
shock response may also require inhibiting HSP70B’ (HSP70-6) which is induced from
the HSPA6 gene. The HSE for HSPA6 gene is sufficiently different from that of
HSPA1A/A1B, however, that a new polyamide would need to be developed. A cocktail
of polyamides that target both the HSPA1A/A1B and HSPA6 promoters could be
investigated in the future, as a way to more completely block induction of the heat shock
response.

Conclusion
We have demonstrated for the first time the ability of a linear polyamide binding in a 1:1
mode to block transcription in vivo. More specifically, a linear polyamide with high
affinity for the heat shock elements 3 and 4 of the HSPA1A/HSPA1B promoter was
developed that interfered with binding of the heat shock transcription factor in vitro and
inhibited heat shock protein 70 induction in vivo. We found that the polyamide design
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that could best accommodate the structural constraints imposed by the G-rich polypurine
tracts of the heat shock element consisted of a linear polyamide with a number of βalanines that was designed to bind in the C→N orientation. Though this polyamide
showed good inhibition of heat shock transcription factor binding in cell lysates,
electroporation was required to observe an inhibitory effect in vivo. Unfortunately, the
multiple β-alanines used to optimize binding affinity may have compromised the ability
of the polyamide to penetrate the cell and/or nucleus. Future work will focus on
improving polyamide cell permeation and further enhancing inhibition of heat shock
transcription factor binding. Given that a considerable amount of heat shock protein may
also be transcribed from the HSPA6 gene, polyamides targeting HSPA6 would also need
to be used in conjunction with polyamides for HSPA1A/A1B to better suppress the heat
shock response.

Experimental section

Abbreviations
HSP: heat shock protein; HSP 70: heat shock protein 70; NF-B: nuclear factor kappalight-chain-enhancer of activated B cells; HSF-1: heat shock transcription factor 1;
CaMKII: Ca2+/calmodulin-dependent protein kinase II; CKII (CK2): casein kinase II;
KNK437: 3-[(E)-1,3-Benzodioxol-5-ylmethylene]-2-oxopyrrolidine-1-carbaldehyde;
SiRNA: small interference RNA; Im: N-methyl imidazole; Py: N-methyl pyrrole; Hp: Nmethyl-3- hydroxypyrrole; HSE: heat shock element; EDTA: ethylenediaminetetraacetic
acid; MPE: methidiumpropyl ethylenediaminetetraacetic acid; PCR: polymerase chain
162

reaction; DnaseI: deoxyribonuclease I; Ka: association constant; Fmoc:
fluorenylmethyloxycarbonyl; DMF: dimethylformaldehyde; DCM: dichloromethane;
UV: ultraviolet ; DIPEA: N,N-diisopropylethylamine; HATU: 2-(7-Aza-1Hbenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; ; HPLC: highperformance liquid chromatography; MALDI: matrix-assisted laser desorption
ionization; EC50: half maximal effective concentration; ODN: oligodeoxynucleotide;
SDS: sodium dodecyl sulfate.

General procedures
Anhydrous dimethyl formamide was from EMD chemicals Inc. Anhydrous
dichloromethane was freshly prepared by refluxing with calcium hydride followed by
distillation. HATU was purchased from Genscript Corporation. All other reagents were
directly purchased either from Omni Solvent or Sigma Aldrich unless otherwise
specified. Amicon centrifugal filters were from Millipore. Analytical thin-layer
chromatography was performed on Aldrich Silica gel 60 F254 plates (0.25 mm). Fmoc
deprotection was qualitatively monitored by UVG-54 mineral light UV lamp at 254 nm.
Chemical synthesis of polyamides
Polyamide building blocks Fmoc-Im-COOH, Fmoc-Py-COOH, Fmoc-Β-alanine and ImCOOH were synthesized according to published procedures as was the manual synthesis
of polyamides with some modifications [21] . Synthesis of the hairpin polyamides was
carried out on an oxime resin in plastic columns (Bio-Rad) that were shaken in an
automatic shaker (Labnet International. Inc) [22], while the synthesis of the linear
polyamides was carried on 200 mg of Fmoc-β-alanine-Wang’s resin, (0.34 mmol/g). One
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synthesis cycle was used for all couplings except when coupling to imidazole, when two
synthesis cycles were used. One cycle of synthesis consisted of Fmoc deprotection
followed by washing, coupling followed by washing, and finally a capping step followed
by washing. Each washing step involved 3-5 mL of solvent. The deprotection step
consisted of mixing the resin with 20% piperidine in DMF and shaking for 3 min. The
deprotection solution was then drained and spotted on thin-layer chromatography plate to
monitor the formation of the Fmoc deprotection product, which turns blue to purple under
a UV 254 nM lamp. The column was then washed with DCM for 3 min followed by
DMF for 3 min, and then 20% piperidine was added again and shaken for additional 20
min. The washing step involved shaking the resin with DCM for 3 min, followed by
DMF for 3 min, repeating again with DCM and DMF for 3 min each and then a final 3
min wash with DMF. The coupling step involved 700 µL of DMF plus 300 µL DIPEA,
containing Im/Py/β building block (0.136 mmol) and a molar equivalent of HATU (0.136
mmol). The building blocks were preincubated with HATU/DIPEA in DMF for 5 min
before adding to the resin. The mixture was shaken for one hour in the case of pyrrole
coupling and two hours in the case of imidazole coupling, while at least 8 h were required
for coupling to imidazole. The capping reagent consisted of 5% pyridine and 20% acetic
anhydride in DMF and was shaken with the support for 3 min, followed by draining and
washing with DCM and DMF for three min each. Additional capping reagent was added
and the suspension was shaken for 20 min before being drained. Before synthesis, resins
were first immersed in a 1:1 DCM/DMF mixture for couple of hours to allow sufficient
time for swelling. At the end of synthesis, polyamides were cleaved from resins (50 mg)
at 55 C by treatment with 2 mL of 1-dimethylaminopropylamine, for 24 h. The 1-
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dimethylaminopropylamine solution was filtered and evaporated to afford a brownish
residue that was triturated with diethyl ether. The yellow to white precipitates were
purified by preparative reverse phase gradient HPLC on a Beckman System Gold HPLC
system with a solvent pump module 125 and model 168 diode array UV detector,
equipped with a reverse phase column XTerra Prep MS C18, (10 µm, 7.8 × 300 mm).
Linear gradients of 0-5 % Solvent B in A over 0.05 min, followed by 5-100% solvent B
in A over 50 min were used, where solvent A was water with 0.1% trifluoroacetic acid
and solvent B was acetonitrile with 0.1% trifluoroacetic acid. The purified products were
characterized by MALDI (Table 4.2) and their purity were also analyzed by HPLC
reverse phase analytical column (Waters XTerra MS C18, 2.5 µm, 4.6×50 mm) using the
same HPLC instrument and solvents as used for purification (Table 4.1). The elution
method was linear gradients of 0-5% solvent B in A over 0.05 min, followed by 5-100%
solvent B in A over 20 min.
Preparation of the DNase I footprinting substrate
The DNA substrate for the DNase I footprinting assays was prepared by polymerase
chain reaction on a HSPA1A containing plasmid [23]. Two primers were chosen with
melting temperatures around 55 C (Left primer d(CACTCTGGCCTCTGATTGGT) and
right primer d(CCCTGGGCTTTTATAAGTCGT)) to give the 152-mer product shown
below.
d(CACTCTGGCCTCTGATTGGTCCAAGGAAGGCTGGGGGGCAGGACGGGAGG
CGAAACCCCTGGAATATTCCCGACCTGGCAGCCTCATCGAGCTCGGTGATTG
GCTCAGAAGGGAAAAGGCGGGTCTCCGTGACGACTTATAAAAGCCCAGGG)
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The left primer was 5'-[32P]-end labeled with kinase and [-32P]-ATP by a standard
procedure. After PCR, the products were cooled in cold block at 4 C and mixed with
Promega blue/orange loading dye (6×), which were then subjected to separation by nondenaturing polyacrylamide gel at a constant voltage of 800 V. The product band was
excised with a razor, immersed in DNA extraction solution (25 mM Tris-HCl /250 mM
NaCl, pH 8.0) and stirred overnight with a stirring bar. The crushed gel pieces were then
filtered by centrifugation on an Ultrafree-CL centrifugal filter (Amicon, Millipore). The
filtrate was equally distributed in 2.0 mL microfuge tubes, to which 1.5 volumes of
isopropanol was added for precipitation at 14000 rpm in cold room, for at least 30 min.
The DNA pellets were further washed with 75% ethanol and centrifuged for 2 min at
14000 rpm. DNA were redissolved in 500 L water and stored at -80 C for further use.
Sequence ladders
The Maxam-Gilbert A+G reaction was carried out according to standard procedures
[24], while the A sequencing reaction was performed according to another procedure
[25]. The A sequencing reaction was carried out by mixing 30 µL of a potassium
tetrachloropalladate(II) solution (32.6 mg of K2PdCl4 in 10 mL of 100 mM HCl solution
that was pre-adjusted to pH 2 with NaOH), with 50 L 5’-end-labeled 152-mer, 1 g
sonicated calf thymus DNA carrier and 120 L water to make a final concentration of 1.5
mM K2PdCl4. After 35 min incubation at room temperature, the reaction was quenched
with 50 L of 2 M sodium acetate, 0.8 M 2-mercaptoethanol and 15 g of calf thymus
DNA. The suspension was precipitated in ethanol and washed with 75% ethanol for
desalting. The yellowish DNA pellet was then dissolved in 50 L freshly made 10%
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piperidine and heated at 90 C for 30 min, before lyophilization in a SpeedVac. To
ensure complete removal of the piperidine, 20 L water was added and the DNA was
redissolved by vigorous vortexing, before being dried again in the Speed Vac. The
product was dissolved in 50 L water and stored at -800C until use.
DNase I footprinting
Footprinting of the polyamides on the DNA was based on a standard procedure [26].
Generally, 300 pmol 5’-endlabelled DNA stock solution was dissolved in TKMC buffer
(10 mM Tris-HCl, 10 mM KCl, 10 mM MgCl2, 5 mM CaCl2, pH 7.0). Polyamide stock
solutions were prepared by serial dilution and 40 L of each was mixed with 350 L of
the DNA solutions. The samples were incubated for 24 h at room temperature to allow
for binding and then treated with 10 L of the optimal amount of DNase I (Invitrogen)
(approximately 1 mU/µL). After 5.5 min the reactions were quenched by treatment with
50 L DNase I stop buffer (30 L 20 mg/mL glycogen II, 0.1mg Calf thymus DNA, 788
L 4 M NaCl, 425 L of 0.5 M EDTA and 137 L water, pH 8.0).
The quenched samples were then ethanol precipitated at 14000 rpm in a cold
room for 30 min, washed with 75% ethanol and redissolved in 20 L water by vigorous
vortexing to ensure full recovery of all the DNA. Samples were immediately mixed with
denaturing loading buffer (1× TBE, 80% formamide) and boiled in water bath for 10 min,
before loading onto an 8% polyacrylamide denaturing gel (7 M urea). Gel
electrophoresis was performed at 2000 V for roughly 2 h until the bromophenol blue
marker completely migrated of the bottom of the gel. After detachment of the glass
plates, the gel was covered with plastic wrap and imaged with phosphor screen for 12 h.
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The screen image was detected with a Biorad Phosphor Imager and processed by
Quantity One software.
Quantitative analysis of footprinting results
The intensity I of bands in the footprinting gels was quantified by Biorad Quantity One
software. The fractional occupation θ by the polyamide was calculated as 1(Isite/Iref)/(Isite/Iref) where Isite is the intensity of a band within the binding site that is
modulated by polyamide, Iref is the intensity of a band outside the binding site that is not
modulated by polyamide binding, and Iosite Ioref are the intensities of the same sites in the
absence of polyamide [26]. The observed fractional occupation as a function of
polyamide concentration (L) was then fit to a variable Hill slope (n) equation with Graph
PadPrism 5 using nonlinear regression analysis (equation 1) and equating EC50 with 1/Ka
and averaged for three independent sets of measurements

(1)   min 

(max  min )
1  10

n (log EC 50 L )

In vitro gel-shift assay of heat shock factor 1 binding
Gel mobility shift assays were performed essentially as previously described [3] using
nuclear extracts prepared from control and heated (43 C for 30 min, 1 h recovery at 37
C.) human HeLa cells. Two complementary ODNs,
d(GTAGGCGAAACCCCTGGAATATTCCCGACCTG) and
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d(CTGCCAGGTCGGGAATATTCCAGGGGTTTCG), derived from the human
HSPA1A gene promoter that contained HSE 1-5 were synthesized and purified by
polyacrylamide gel electrophoresis (Eurofins). After annealing, the 5’-overhanging ends
of the duplex DNA were filled with -32P-dATP and cold nucleotides using Klenow
polymerase to give a 36-mer radiolabelled duplex. Polyamides (10-500 nM) were bound
to the labeled duplex ODNs (10 nM) by incubation together in annealing buffer (10 mM
Tris pH 7.5, 10 mM NaCl, 1 mM EDTA) for 16 h at 25 C. Mobility shift binding
reactions containing 1.5 g of nuclear proteins mixed with equivalent counts of labeled
probe in a 25 L final volume were incubated for 20 min at 25 C before separation on
4.5% polyacrylamide gels. Labeled protein-DNA bands were detected and quantified on
a Molecular Dynamics PhosphoImager.
Electroporation of polyamides
Approximately 2 × 106 human Jurkat cells were resuspended in 100 L electroporation
buffer (Amaxa, Inc.) with 5 M polyamide and electroporated in an Amaxa Nucleofector
using program I-010. Cells were re-plated in 5 mL RPMI media plus 5 M polyamide
and cell viability determined by trypan blue exclusion 24 h later. Cells were then heated
at 43 C. for 30 min and allowed to recover at 37 C for 6-8 h before being harvested in
Laemmli buffer for protein analysis.
Western blot assay
Proteins were separated on 7% SDS-polyacrylamide gels and transferred to ImmobilonP membranes and probed with mouse anti-HSP70 (SPA-810, Assay Designs) and mouse
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anti-actin (C4, MP Inc) followed by AP-coupled goat anti-mouse. Band intensity was
quantified by scanning on a BioRad ChemDoc XRS.
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Table 4.1 HPLC analysis of polyamides.
310 nM
Polyamide

280 nM

254 nM

Retention
time /min

Purity /%

Retention
time /min

Purity /%

Retention
time /min

Purity /%

P1

8.183

97.39

8.183

100

8.133

100

P2

8.167

99.14

8.167

98.46

8.083

97.50

P3

8.467

97.35

8.467

96.89

8.467

95.79

P4

7.633

99.56

7.633

99.31

7.633

98.57

P5

7.400

96.39

7.383

98.05

7.400

98.62

P6

8.317

98.15

8.317

99.16

8.317

99.74

P7

6.633

95.89

6.633

98.74

6.633

96.13

P8

8.000

96.22

8.000

97.23

7.983

100

P9

7.267

95.98

7.267

99.14

7.267

99.10

P10

8.950

99.87

8.967

99.80

8.983

99.80

P11

7.267

95.63

7.267

95.73

7.250

98.14

P12

8.000

97.93

8.000

97.49

7.900

100

H0

7.533

99.25

7.533

96.34

7.533

97.74

H1

7.600

97.77

7.600

99.19

7.600

100

H2

7.067

98.95

7.067

99.32

7.033

96.48

H3

7.617

98.66

7.617

98.20

7.617

97.29
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Table 4.2 MALDI MS analysis of polyamides. Expected monoisotopic
(M+H)+ versus observed (M+H)+.
P1

P2

P3

P4

Formula

C45H58N17O8

C45H58N17O8

C45H58N17O8

C44H60N17O9

(MW+H)+

964.4654

964.4654

964.4654

970.4760

964.6

964.5

964.6

970.4

P5

P6

P7

P8

Formula

C42H57N16O8

C45H58N17O8

C35H49N14O7

C50H66N19O10

(MW+H)+

913.4545

964.4654

777.3909

1092.5240

913.4

964.4

777.3

1092.5

P9

P10

P11

P12

Formula

C42H57N16O8

C48H59N18O8

C42H57N16O8

C50H66N19O10

(MW+H)+
(expected)

913.4545

1015.4760

913.4545

1092.524

(MW+H)+

913.5

1015.5

913.6

1092.6

(expected)
(MW+H)+
(observed)

(expected)
(MW+H)+
(observed)

(observed)
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H0

H1

H2

H3

Formula

C55H68N21O9

C55H68N21O9

C49H66N19O9

C49H66N19O9

(MW+H)+

1166.5508

1166.5508

1064.5291

1064.5291

1166.2

1166.6

1064.5

1064.7

(expected)
(MW+H)+
(observed)
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Table 4.3 Association constants and Hill slope coefficients for the linear polyamides
Polyamide

Length

Ka (M-1)

Hill Slope
coefficient

P5

8

1.39 ± 0.46 × 107

0.89 ± 0.18

P9

8

8.84 ± 0.35 × 106

1.53 ± 0.18

P7

6

1.15 ± 0.24 × 107

0.95 ± 0.28

P4

8

1.19 ± 0.90 × 108

0.68 ± 0.41

P8

9

3.44 ± 1.4 × 108

0.86 ± 0.42
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Figure 4.1 Polyamide structure, binding, and synthetic intermediates. a) Polyamides are
composed of N-methyl-imidazole (Im), N-methyl-pyrrole (Py) and β-alanine (β) that recognize
DNA sequences through hydrogen bonding to the minor groove of Watson-Crick base pairs by
side pairing of Im/Py for G/C, Py/Im for C/G, and Py/Py for A/T or T/A, respectively. The more
flexible β/β can also recognize A/T or T/A. b) The Fmoc aminoacids used to synthesize
polyamides. Im-CO2H is used when the N-terminal amino acid is N-methyl-imidazole.
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(a)

HSE1

HSE3

HSE5

5’-CGAAACCCCT GGAAT ATTCC CGACCTGGCA-3’
3’-GCTTTGGGGA CCTTA TAAGG GCTGGACCGT-5’
HSE2

5’-C T G G
Im Im
Dp X X
3’- G A C C

H1

Im Im Py Py
Dp Py Py Py Py

H0

Im Py Im Py
Dp Py Py Py Py

A
X
X
T

A T A
X
X
+
T A T
+

(b)

HSE4

+

+

T
X
X
A

T
X
X
A

C C C G-3’
X X Dp
Im Im
G G G C

H2

Im Im β Py
Dp Py Py β Py

+

H3

Im Im Py β
Dp Py Py Py β

+

Figure 4.2 Design of polyamide libraries targeting the promoter region of DNA encoding for
heat shock protein 70. a) The promoter region of the human heat shock protein A1A/A1B gene
contains five adjacent heat shock elements (HSE), which binds to the trimerized form of heat
shock transcription factor 1 (HSF1) in its major groove. HSE3 and HSE4 combine to form a
pallindromic site (boxed) with the dyad axis indicated with a filled diamond. b) Hairpin
polyamides targeted to the minor groove of the GGAA sequence.
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(c)
P10
P1
P2
P3
P6
P5
P9
P11
P8
P4
P7
P12

-7 -6 -5 -4 -3 -2 -1 1 2 3 4 5 6 7
5’-C T G G A A T A T T C C C G-3’ top
strand
Im Im Py Py Py Py Py  Dp+
Im Im  Py Py Py Py  Dp+
Im Im Py  Py Py Py  Dp+
Im Im Py Py  Py Py  Dp+
5’→3’
Im Im Py Py Py  Py  Dp+
N→C
Im Im  Py Py  Py  Dp+
Im Im Py  Py  Py  Dp+
Im  Im Py Py  Py  Dp+
+Dp  Im Im  Py Py  Py Py Ac
5’→3’
+Dp  Im Im  Py Py  Py Ac
C→N
+Dp  Im Im  Py Py Ac
+Dp  Im  Im Py Py  Py Py Ac
bottom
5’-C G G G A A T A T T C C A G-3’
strand

Figure 4.2 Design of polyamide libraries targeting the promoter region of DNA encoding for
heat shock protein 70. c) Linear polyamide libraries designed to target the minor groove of heat
shock elements HSE 3 and HSE 4. The orientation of the polyamide (N→C or C→N) with
respect to the top strand (5’→3’) is shown to the right, and mismatches in the polyamide are
underlined. Polyamides 1-3, 5-6 and 9-10 can also bind to the bottom strand shown below in the
reverse orientation with respect to the top strand
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(a) H0,H2,H3
C

(b) H1

A

C

A
E

4
3
2
1

Figure 4.3 DNase I footprinting of the hairpin polyamide library. a) Representative denaturing
polyacrylamide gel for H2, H3, and H0. The concentration of polyamide increased from left to
right: 0, 10, 50, 100, 500 pM, 1, 5, 10, 50, 100, 500 nM, 1µM. b) The concentration of polyamide
H1 increased from left to right: 0, 100, 200, 300, 400, 500 nM. C is a control with no polyamide
or DNase I, A is the Maxam Gilbert A sequencing lane. Binding sites are labeled according to the
scheme shown in panel c below.
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(c)

A
GAAGGCTGGGGGGCAGGACGGGAGG
1
2
3
4
5
CGAAACCCCTGGAATATTCCCGACC
C
B
TGGCAGCCTCATCGAGCTCGGTGAT
D
E
TGGCTCAGAAGGGAAAAGGCGGGTC
TCCGTGACGACTTATAAAAGCCCAG

Figure 4.3 DNase I footprinting of the hairpin polyamide library. c) Sequence of the 152-mer
(only 26150 shown) with HSE sites indicated as numbers 1-5, as well as other sites observed to
be bound by the hairpin and linear polyamide, as letters A-E. The A’s that appear in the
sequencing lanes are underlined.
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(a) P1, P2, P3,
P6, P10
C

(b) P5, P9
A

C

(c) P11
A

C

A

4
3

Figure 4.4 DNase I footprinting of the N→C linear polyamide library. Polyamide concentration
increases from left to right at 0, 0.1, 1, 10, 50, 100, 200, 300, 400 and 500 nM. Lane C is a
control lane containing only DNA and 500 nM polyamide and no DNase I. Lane A is the Maxam
Gilbert A sequencing reaction lane. Gel a) shows the footprinting of P10 which is representative
of P10, P1, P2, P3 and P6. Gel b) illustrates the footprinting of P9 which is representative of P5
and P9, and gel c) is the result of the mismatch control P11. Binding sites are labeled according
to the scheme shown in Figure 4.3c.
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P7
C

P4
A

C

P8
A

C

E
D

4
3

P12
C A Ct

A

E
D
C
B
4
3

4
3

E
D
C

4
3
2
1
A

Figure 4.5 DNase I footprinting of the C→N linear polyamide library. Polyamide concentration
increases from left to right at 0, 0.1, 1, 10, 50, 100, 200, 300, 400 and 500 nM. Lane C is a
control lane with DNA and 500 nM polyamide and no DNase I. Lane A is the Maxam Gilbert A
sequencing reaction. P12 is the mismatch control for P7, P4 and P8. Binding sites are labeled
according to the scheme shown in Figure 4.3c.
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Figure 4.6 Analysis of the DNase I footprints of P4, P7 and P8 at HSE3 and HSE4. The bracket
to the left indicates sites that become progressively blocked on going from P4 to P7 to P8. To
align the DNase I bands with the A sequencing lane, one has to take into account that the DNA is
5’-end-labeled and that DNase I cleaves to the 3’-side of a nucleotide producing a 5’-end-labeled
product with a 3’-OH. The Maxam Gilbert A reaction, on the other hand, cleaves to the 5’-side of
the nucleotide and produces a 5’-end-labeled product with a 3’-phosphate. Because the a 3’phosphate increases the mobility of a DNA fragment relative to a 3’-OH by about one nucleotide
or more [37, 38], the band corresponding to cleavage to the 3’-side of an A by DNase I
corresponds to a band about 2 nt higher up on the gel than produced by a Maxam Gilbert A
reaction.
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Figure 4.7 DNase I footprinting of polyamide P4 and P8 at lower concentrations for quantitative
footprinting analysis. From Left to right, polyamide concentration increased as 0, 10, 50, 100,
500, and 800 pM, 1, 2, 5, 10, and 100 nM. “C”, control DNA with 100 nM polyamide but no
DNase I addition; “A” Adenosine sequencing of DNA substrate.
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Figure 4.8 Curve fits of the percentage of “site occupation” or “DNaseI inhibition” versus
polyamide concentration for P4, P7, P8, P5 and P9. Fits were generated by GraphPad Prism
using a variable Hill slope equation with nonlinear regression analysis.
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Figure 4.9 In vitro gel-shift assay of block of heat shock factor 1 binding by polyamides.
Polyamides P1-P10 along with mismatch control P11 and P12 were tested each on their ability to
block the binding of HSF-1 to its cognate HSE DNA promoter at a concentration of 100 nM.
Radiolabeled HSE oligodeoxynucleotide (10 nM) was incubated with each polyamide at 100 nM
for 16 h before mixing with nuclear extracts (1.5 µg protein) prepared from heated Jurkat cells
(43 °C for 30 min with 30 min recovery at 37 °C.) and the formation of HSE/HSF-1 complexes
determined by gel electrophoresis. Control lane C: radiolabeled oligodeoxynucleotide, in the
absence of added polyamide, mixed with Jurkat extract from heated cells.
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Figure 4.10 In vitro gel-shift assay of heat shock factor 1 binding in presence of P8, P11 and
P12. Titration of the effective concentration of polyamide P8 against (a) mismatch control
polyamide P11 and (b) mismatch control P12 for inhibition of heat shock factor/heat shock
element complex formation was performed using nuclear extracts prepared from heated (43 C
for 30 min, 1 h recovery at 37 C) human HeLa cells. Polyamides were incubated with a 32Pradiolabeled 36-mer duplex DNA substrate containing the five heat shock elements in annealing
buffer (10 mM Tris pH 7.5, 10 mM NaCl, 1 mM EDTA) for 16 h at 25 C.

Lane O is a DNA

control without addition of nuclear extract. Lane C is a DNA control mixed with non-heated
nuclear extract. Lane H is a DNA control with heat extract proteins but no added polyamide.
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Figure 4.11 Polyamide inhibition of HSP70 expression in vivo. (a) Jurkat cells were
electroporated with 5 M P11 or P8 and then allowed to recover for 24 h in 5 M polyamide
before being heat shocked at 43 C for 30 min to induce HSP70 gene transcription and protein
synthesis. Western blot analysis was performed with mouse anti-HSP70 and mouse anti-actin
followed by AP-coupled goat anti-mouse. Lane C is control cells without heat, lane HS is control
cells with heat shock. (b) Band intensity on western blot was quantified by scanning on BioRad
ChemDoc XRS. Percent of induced HSP70 was normalized to actin protein levels and corrected
for cell viability. P8 treatment decreased HSP70 levels to 60% of normal.
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Chapter 5.
Summary, Conclusions, and Future Studies
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In this dissertation, we were interested in developing methods for inhibiting heat shock
protein 70 (HSP70) which is considered an emerging drug target. In previous literature
reports [1], its nucleotide binding domain is known to bind ATP with high affinity and
thus make it difficult to replace it with drug-like molecules specific for HSP70 alone.
This fact, together the fact that both its nucleotide binding domain and substrate binding
domain are also highly hydrophilic, make the overall druggability of heat shock protein
70 (HSP70) poor [2]. Since heat shock protein 70 is only expressed at low levels in most
cells except cancer cells, but is highly inducible when cells are under stress [3], our
attention focused on inhibiting the induction of HSP70 by interfering with the activation
or binding of the heat shock transcription factor. Inhibitors of HSP70 induction might
therefore be better and more feasible drugs for cancer chemotherapy.
The goal of this dissertation was therefore to develop both small molecule
inhibitors and gene inhibitors that specifically inhibit the induction of heat shock protein
70 by interfering with the activation of transcription. We also expected the inhibitors
that we developed to better understand the underlying pathways of heat shock protein 70
induction, and identify other key proteins that might be involved that can serve as future
targets for drug design.
Of all known natural products that can inhibit the induction of heat shock protein 70,
quercetin has very low toxicity and has the advantage of being easily modified. Our first
goal was therefore to carry out the structure and activity studies of quercetin derivatives
to identify derivatives specific for HSP70 inhibition that could be potentially developed
to chemotherapeutic drugs, and in the process to also map out the non-active sites on
quercetin for attachment of biotin probes to pull down potential target proteins of
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quercetin. As a result of my efforts, I successfully synthesized the mono-methyl, monocarbomethoxy methylate and mono-carboxymethylate derivatives of quercetin. In
collaboration with Dr. Clayton Hunt who tested their ability to inhibit HSP70 induction,
we were able to identify two mono-derivatized classes of inhibitors having one of the
hydroxyl groups modified (D1, D2 on 3’-OH; D7, D10 on 7-OH) that retained the ability
to inhibit HSP70 induction. We also discovered that quercetin enhances the
phosphorylation of HSP27 required for its anti-apoptotic action in cells to diminish the
radiosensitizing or antitumor effects of inhibiting HSP70 induction. Two derivatives
(D1 and D2), unlike quercetin, could also inhibit HSP70 induction without enhancing
HSP27 phosphorylation. D1 and D2 could thus be candidates with more specificity for
future drug development although the degree of their enhancement in different
chemotherapy, anti-cancer therapy remains to be determined. In the course of evaluating
these derivatives, I also discovered that their ability to inhibit HSP70 induction is related
to their ability to inhibit both CK2 and CaMKII kinases that are known to phosphorylate
heat shock transcription factor 1 [4]. This suggests that the ability of quercetin to inhibit
HSP70 induction is due to its lack of specificity, rather than to high specificity which is
commonly thought to be important for drug design, and may represent a new paradigm
for drug design. This would also suggest that in the future, inhibitors for HSP70
induction could be found by screening for their ability to inhibit both CK2 and CaMKII
kinases.
The second goal of this dissertation was to identify other possible targets of quercetin
by attaching a biotin affinity label to the non-active sites of quercetin to enable us to pull
down target proteins from cells. I demonstrated the feasibility of this approach by
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conjugating biotin to the O7- position and showed that this probe (called BioQ) can be
used as a photoaffinity agent to pull down CK2 in vitro and quercetin binding proteins in
vivo through the use of steptavidin beads. I made use of quercetin’s intrinsic
photoreactivity to enable covalent binding of the quercetin moiety to target proteins to
enable us to pull down low-affinity binding proteins as well as to make it possible to
wash away non-specifically bound proteins. Using this probe, we discovered that many
of the proteins that we pulled down have already been identified as potential therapeutic
targets in cancer therapy suggesting that quercetin acts as an anticancer agent by
interfering with many cancer pathways. The proposed targets CK2 and CaMKII were,
however, not identified presumably because they were present at too low a level. Further
studies of the photocrosslinking mechanism and amino acid specificity are also
necessary. In the future, biotin probes will be constructed by linking to the other
available hydroxyl sites on quercetin and additional photocrosslinking agents may be
added to enhance the photocrosslinking efficiency. To confirm the identities of the
protein candidates pulled down, western blot assays could be conducted. Finally a
protein knock-out or knock-down studies could be carried out to verify the protein targets
as viable targets for chemotherapy.
Another goal was to develop polyamide based anti-gene inhibitors of heat shock
protein 70 induction. Towards this goal I designed and synthesized a library of
polyamides aimed at blocking binding of the heat shock transcription factor 1to the heat
shock promoter. After characterization of the binding specificity and affinity with DNase
I footprinting and an in vitro transcription factor 1 binding study, I was able to identify
one linear polyamide with high affinity for the heat shock elements 3 and 4 of the
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HSPA1A/HSPA1B promoter. This polyamide binds to the twisted polypurine rich
region in an unusual 1:1 mode and in the C→N orientation. Despite the in vitro
performance, this linear polyamide was not able to efficiently penetrate cells and/or the
nucleus, though we could show that it could inhibit HSP70 induction by about 40% by
electroporation. Future work could focus on attaching some cell penetrating peptides to
help cell permeation. To achieve complete knock down of HSP70 it may also be
necessary to block binding to the HSPA6 promoter which has a different sequence from
the HSPA1A/A1B promoter. Inhibition of HSP70 induction could then be carried out
with a cocktail of these two polyamide inhibitors.
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